Articles
-
All
-
Scientific Reviews
-
EDM
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
The concept of ADC can be traced back to the early 1900s, It is a visionary magic bullet that could deliver a toxic drug to certain malignant cells without affecting other normal tissues. Now, it seems that a golden age of ADC drug development is coming.
-
PROTAC, which exploit the ubiquitin-proteasome pathway to specifically degrade target proteins. PROTACs not only solve the problem of undruggability but they also have other advantages compared to traditional drug targeting strategies.
-
PROTAC — Target Selection and Design
2022-07-08
A PROTAC molecule consists of three components: a target protein binding ligand, an E3 ligase ligand, and a linker connecting these two moieties. Here, we will discuss the conventional approaches for the rational design of PROTAC molecules. -
Organoids represent an important bridge between 2D cultures and in vivo mouse/human models. The organoid technology exerts enormous potential in evaluation of efficacy and toxicity of drugs, regenerative medicine, and precision medicine.In this article, we will briefly introduce organoid technology.
-
Development of Intestinal Organoid
2022-07-28
3D organoid is one of the revolutionary developments in biomedical field during the past 10 years. The establishment of intestinal organoids is an important milestone in the development of organoid technology. -
BacPROTACs is composed of a POI ligand, a chemical linker and a ClpCNTD anchor. BacPROTACs can induce in vitro and in vivo degradation of non-eukaryotic proteins in bacteria without the ubiquitin proteasome system.
-
RNA therapeutics have changed the landscape of drug development, which possess broader spectrum of drug targets, simplicity and efficiency in development and manufacturing.In this article, we will discuss the underlying mechanisms of RNA-based drugs on the market or in clinical stages.
-
Tsvetkov et al. published in Science and demonstrated a copper-induced programmed cell death — Cuproptosis. As a novel programmed cell death, excess copper triggers abnormal aggregation of lipoylated proteins in TCA cycle and clearance of Fe-S cluster proteins, ultimately leading to cell death.
-
A comprehensive explanation of ferroptosis
2022-09-15
Ferroptosis is a new type of RCD that depends on iron and characterized by the accumulation of lipid peroxides. In this article, we will pay our attention on ferroptosis and briefly discusses its mechanism. -
It's has been proved that p53, as a tumor suppressor gene and immune guardian, may become a destroyer through its own mutation. Moreover, the mechanism of p53 was found to be related to ferroptosis. This article mainly explores the mechanism between p53 and ferroptosis in detail.
-
Organoids have great potential in research of organ development, disease modeling, drug screening and, precision and regenerative medicin. In this article, we will expalin the origin of the organoids. Adult stem cells (ASCs) or pluripotent stem cells (PSCs) , which is the better choice.
-
Autophagy, derived from the Greek meaning "eating of self", plays an indispensable role in maintaining homeostasis. p27 is an inhibitor of cyclin CDKs, but how p27 regulates autophagy remains unknown. This article will cover the mechanism of autophagy and p27-related cell cycle regulation.
-
CMA (chaperone-mediated autophagy) plays an essential role in maintaining neuronal protein stability and preventing neurodegeneration. In this article, we will comprehensively clarify the role of CMA in the occurrence and development of neurodegenerative diseases.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
As powerful pain relievers, the opioids morphine and fentanyl have been "checked" by their side effects (listed as controlled substances). How to reduce its side effects? What is its mechanism? This research will explore its mechanism.
-
Efferocytosis is the process in which phagocytes remove programmed dead cells. It prevents secondary necrosis of dying cells from releasing harmful cell contents (such as oxides and proteases) that may cause inflammation. Here, we will introduce three stages of efferocytosis: Find, Eat, Digest.
-
Understanding the mechanism of aging not only has guiding significance for prolonging human life but also has important clinical significance for the prevention and treatment of diseases in the elderly population , thus, improving their life quality and well-being.
-
Mammalian cells can also photosynthesize like plants! Photosynthesis can improve cell anabolism and exhibit good clinical effect in degenerative diseases (osteoarthritis).
-
The latest study of Cell magazine "Neural mechanism underlying depressive-like state associated with social status loss" considers social factors as a breakthrough point. It has been found that the downward transition of social status induces depression-like behavior in mice whereas improves the depressive state by restoring their social environment.
-
PROTAC - Design Strategy for Targeting
2023-04-23
Protein degradation targeting chimera (PROTAC) is a technology that uses the ubiquitin proteasome pathway to silent target protein. However, PROTAC still has problems such as solubility, membrane permeability, and selectivity. In this article, we have summarized three strategies for optimization: light-controlled linker, PAC molecule, and specific E3 ligase. -
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
Stem cell classification and its application
2023-05-18
Stem cells (SCs) have the unique ability to self-renew and differentiate into different cell types. SCs can differentiate into various types of tissue cells under specific conditions. Additionally, they can be further cultured to form different tissues and organs in the human body. Stem cells have numerous applications in various fields, including cell therapy, organ transplantation, neurodegenerative disease modeling, and drug screening. -
Mitophagy:Mechanisms and Detection
2023-05-25
About 60 years ago, Christian de Duve first used the term "autophagy" to describe his observation of the degradation of mitochondria and other intracellular structures in lysosomes of rat liver. Over the years, autophagy has remained a beloved topic of research by the National Natural Science Foundation of China (NSFC).Today, let's talk about mitochondrial autophagy. -
Structure of Lipid Droplets
2023-06-15
Huh? Lipid droplets? Organelles? In the past, biological data usually only show the traditional organelles, such as mitochondria, Golgi apparatus, endoplasmic reticulum, etc., lipid droplets are often not mentioned by people. Today, we will make a systematic explanation of lipid droplets, so that everyone has a clear understanding! -
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
Organoid Culture: Questions & Answers
2023-07-26
In the last issue, we conducted a live lecture on the theme of organoid culture. Today, we have a special topic to solve your doubts in the last live class! -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
Are frozen cells always damaged? Is the survival rate of revived cells low? When is it appropriate to freeze cells? What should be considered when reviving them? Today, we're sharing a guide to avoid pitfalls in cell freezing and revival!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
Science | A "new" mechanism for non-ubiquitinated Midnolin-proteasomal degradation pathway
2024-04-26
“ubiquitin-mediated protein degradation” won the Nobel Prize in Chemistry in 2004! In fact, proteasomes degrade not only ubiquitinated proteins but also non-ubiquitinated ones. The mechanism remains shrouded in mystery. After reading this piece today, you might have a lightbulb moment! -
Still struggling to find the preparation methods for various solutions? Save your time! Here comes a nanny-level tutorial!
-
STZ Induced Diabetes Models
2024-06-13
Spotlight: How can STZ Help Diabetes Research? -
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
Degrade target proteins through the autophagy-lysosome pathway including LYTAC, AUTAC, and ATTEC have gained increasing attention in recent years due to their significant research potential!
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
Science’s 2023 Breakthrough: GLP-1R Agonists
2024-08-13
GLP-1RAs, which achieved great success in 2023 and draws people’s attention back to obesity treatments and GLP-1 therapies worldwide, was chosen as the breakthrough of year 2023 by Science [2]. -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Cuproptosis, How much do you know?
2024-08-22
Cells die in a variety of ways, including apoptosis, pyroptosis, necrosis, and ferroptosis......And, of course, cuproptosis. So, how much do you know about cuproptosis? -
Recently, Mol Cell reported the discovery of the first ferroptosis marker, Hyperoxidized PRDX3! Let’s take a look together~
-
Cuproptosis's Knowledge Points!
2024-09-25
With the establishment of the cuproptosis mechanism related research has attracted more and more attention from major journals. Expect to use the sharp sword of cuproptosis to stab the tumor cells. -
How they used PKH 26 for cellular studies?
2024-10-21
We are thrilled to highlight our client study using PKH 26 (MedChemExpress) , a red fluorescent dye that has proven invaluable for in vitro cell labeling and tracing. This innovative research, published in the Journal of Nanobiotechnology. -
Delve into the intricate networks that govern mitochondrial quality control. By examining key mechanisms such as biogenesis, mitochondrial dynamics (fission and fusion), proteolysis, and mitophagy.
-
A New Form of Cell Death: PANoptosis!
-
Unlocking the Power of Intermittent Fasting: The 16+8 Method
-
Advancing Chronic Kidney Disease Research with GJ103 and Lamin B1 Antibody!
-
When you hear "inflammation" and "DNA damage," you might immediately think of disease or injury. However, in brains, these two processes are key steps in forming long-term memories, particularly related to specialized cells in our brain called hippocampal neurons.
-
Autophagy is a fundamental process that degrades various components within the cell.
-
This article will tell you about the common methods of modeling liver disease in animal models.
-
nside cells, the homeostasis and degradation of proteins is a precisely regulated process. If proteins cannot be degraded in time, it may lead to the occurrence of various diseases such as neurodegenerative diseases and cancer. This article will tell you the process of how proteins are recognized, labeled and then degraded!
-
This article will walk you through the remarkable impacts of anti-payload antibodies, delving into how these molecules are revolutionizing drug development and biological research!
-
This article introduces some common cardiovascular disease models, inducers, modeling protocols and successful modeling cases in the research.
-
Do you feel confused when you start culturing cells? This article will show you the basic methods and steps of cell culture!
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
In this issue, we will conduct an in-depth interpretation from the dimensions of nanoparticle design, mechanism of action, in vivo and in vitro efficacy, and immune regulation, revealing how this research brings new hope for the treatment of invasive tumors through interdisciplinary innovation!
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
The article introduces the mechanisms of ROS generation and the methods for their detection.
-
Have you ever noticed that after staying up late, your appetite—especially for high-calorie foods—gets out of control? If this sounds familiar, today’s article might offer some good news.
-
Generating Stable Cell Lines with Lentivirus
2025-09-16
A step-by-step protocol of establishing stable cell lines using lentivirus -
A groundbreaking study in Nature Communications reveals the key mechanism behind Idiopathic Pulmonary Fibrosis and identifies an existing drug with the potential to counter it.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
Finding adipogenic induction media too expensive and tricky to prepare? This comprehensive guide to 3T3-L1 adipogenic differentiation simplifies the process, helping you achieve great results!
-
Microglia– the only immune cells within the brain parenchyma. With advancements in imaging technologies, people’s understanding of microglia has shifted from being viewed as 'resting' cells to 'highly active' cells, particularly due to their dynamic processes that seem to be probing surrounding tissues and monitoring neuronal activity. This has made microglia a focal point of research in the field of neuroscience.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
Efficient Generation of Mouse Small Intestinal Organoids: A Complete Experimental Protocol Guide
2025-12-10
How to successfully create mouse small intestine organoids? A detailed, hands-on guide to the entire process, all in one article! -
A November 2025 Cell study discovers Mitoxyperilysis, a new mTOR-regulated, caspase-independent cell death pathway driven by innate immune and metabolic dysregulation via mitochondrial-plasma membrane contact and oxidative damage, and verifies its potential to induce tumor necrosis for cancer therapy with key regulators including BAX, BAK1 and BID.
-
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
In the hunt for the next ‘GLP-1,’ amylin therapeutics, which have shown strong weight-loss results in clinical trials, have become a major focus for both multinational pharma and the scientific community.
-
Essential for High-Impact Papers: Present Your CCK-8 Experimental Results in a More Outstanding Way!
2026-03-18
CCK-8 is a widely used WST‑8‑based reagent for cell proliferation and cytotoxicity assays. It features high sensitivity, reliable results and easy operation, and is applicable to cell viability analysis, drug screening and growth inhibition testing. -
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
GLP-1 and Obesity Research
2026-08-14
Obesity substantially increases the risk of chronic diseases such as T2D and cardiovascular disease. The breakout success of GLP-1 therapies has spotlighted GLP-1R and a wave of emerging obesity targets. -
Research Solution for Breast Cancer TME
2025-05-21
This review examines the complex interactions within the breast cancer tumor microenvironment, emphasizing how understanding these dynamics is essential for developing effective therapies and overcoming immune resistance. -
This review discusses the fundamentals of lipid biology and lipid metabolism, examines dysregulated lipid metabolism in cancer, and summarizes therapeutic strategies targeting lipid metabolic pathways.
-
This review critically examines the role of the JAK-STAT pathway in immunity and autoimmune diseases, reviews current clinical applications of targeted therapies, and highlights emerging trends in autoimmune drug development.
-
This review summarizes the mechanisms of DSS-induced colitis, commonly used modeling approaches, and key considerations related to DSS molecular weight.
-
Combating Immune Evasion in Cancer
2025-10-15
This review summarizes the mechanisms by which tumors evade immune surveillance and discusses therapeutic strategies to restore antitumor immunity. -
This review summarizes the mechanisms of drug resistance in triple-negative breast cancer and highlights emerging therapeutic strategies.
-
Bispecific Antibodies in Cancer Therapy
2025-10-29
This review highlights the mechanisms, technology platforms, and clinical progress of bispecific antibodies, and discusses emerging strategies to guide future development. -
This review provides insights into the pancreatic ductal adenocarcinoma tumor microenvironment, highlighting its cellular composition, stromal heterogeneity, and immune-targeting strategies.
-
This review outlines macrophage functions and classification, and provides practical experimental guidelines for macrophage differentiation, polarization, and identification.
-
Highlight single-cell metabolomics and stable isotope tracing (SIT) in uncovering metabolic heterogeneity and nutrient flux dynamics in tumors.
-
Tumor Organoid-Immune Cell Co-Culture Models: Advances, Applications, and Future Directions
2026-05-07
Summarize technical strategies, application advances, and future directions of tumor organoid–immune co-culture systems. -
Review mechanisms, major challenges, and efficacy-enhancing strategies of TCR-T therapy in solid tumors, with implications for future research and clinical translation.
-
The Dual Role of Cellular Senescence in Cancer: Mechanisms, Microenvironment, and Therapeutics
2026-05-21
Explore the dual role of cellular senescence in cancer, including tumor suppression, SASP-driven tumor promotion, senescence heterogeneity and plasticity, and advances in senescence-targeted therapies. -
Explore lysosomal nutrient sensing, quality control, cellular adaptation, disease mechanisms, and emerging therapeutic approaches.
-
Review the mechanisms, mitochondrial regulation, disease relevance, and translational opportunities of the NLRP3–STING axis in neuroinflammation.
-
Breaking Immune Resistance in Colorectal Cancer: From Molecular Mechanisms to Precision Therapy
2026-06-25
Explore CRC molecular subtypes, immune landscapes, resistance mechanisms, and emerging precision strategies for improving outcomes across distinct subtypes. -
Explore the mechanisms driving immune tolerance breakdown in autoimmune diseases and emerging tolerance-restoring strategies, with a focus on IL-2-based immune modulation.
-
Explore how mitochondrial quality control, inflammatory signaling, and metabolic–epigenetic reprogramming regulate cellular senescence and the SASP, along with strategies to restore mitochondrial homeostasis.
-
EC0489, a SMDC for Cancer Therapy
2019-03-25
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a SMDC under development for the treatment of solid tumours. -
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy.
-
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
Alofanib, An Allosteric Inhibitor of FGFR2
2019-03-28
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
A Novel and Efficacious RAF Inhibitor RAF709
2019-03-30
RAF709, a novel and efficacious RAF inhibitor, activates the MAPK pathway and shows antitumor activity in tumor cells harboring BRAF or RAS mutations. -
AZD3229 is a Potent Pan-KIT Mutant Inhibitor
2019-04-04
AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines. -
BR351 is a Brain Penetrant MMP Inhibitor
2019-04-05
BR351 is a brain penetrant MMP inhibitor, and a potential tool for the molecular imaging of activated MMPs with PET, with an IC50 in the nanomolar range. -
SGC-GAK-1 is a potent, selective, and cell-active GAK inhibitor and shows potent anti-proliferative activity in LNCaP and 22Rv1 cells.
-
COH000 is an allosteric, covalent and irreversible inhibitor of SUMO-activating enzyme, with an IC50 of 0.2 μM for SUMOylation in vitro.
-
HS-1371 is a Small Molecule RIP3 Inhibitor
2019-04-09
HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis, showing an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. -
MK-0429 is An Oral Integrin (αvβ3) Inhibitor
2019-04-11
MK-0429, an orally active αvβ3 inhibitor, is a potential therapeutic agent for the prevention of kidney fibrosis, melanoma and osteoporosis. -
AZ304, a Dual BRAF Inhibitor Against Cancer
2019-04-12
AZ304 is a potent BRAF inhibitor, blocks both wild type BRAF and V600E mutant BRAF activity, with IC50s in the nanomolar range. -
IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ.
-
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
(E)-AG 99 is an EGFR inhibitor and shows a growth-inhibition on not only serum-starved cells but also normally grown cells. Treatment for Bladder cancer.
-
BTR-1 potently inhibits cell growth. It induces S phase arrest, affects DNA replication. Dose-dependently induces cytotoxicity in leukemic cell lines.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Akt-wt.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
SLLN-15 is an oral activ enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
-
BAY-8002 is a selective and orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM. Has potential to treat lymphoma.
-
MRTX-1257 is a selective, irreversible, covalent and oral active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation.
-
USL311 is a selective CXCR4 antagonist, which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. Anti-tumor activity.
-
TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling
2019-06-01
TX1-85-1 is a Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. -
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM. Potently blocks the TNF response and RIP1-dependent inflammatory cytokine MIP-1β production.
-
JMS-17-2 is a CX3CR1 Antagonist
2019-06-12
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. Has potential to treat cancers such as breast cancer. -
Ralimetinib (LY2228820) is a selective and ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Anti-tumor activity.
-
BAY-11-7082 inhibits the proliferation and induces the apoptosis of U266 cells through inhibiting NF-κB pathway. BAY 11-7082 ameliorates experimental diabetic neuropathy by modulating neuroinflammation and improving antioxidant defence.
-
S130, Targeting ATG4B, Inhibits Autophagy and Activates Apoptosis in Colorectal Colon Cancer
2019-06-19
S130 is a high affinity, selective inhibitor of ATG4B (a major cysteine protease) with an IC50 of 3.24 µM. S130 suppresses autophagy flux. -
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
PTC299 is a dual and orally active DHODH and VEGF inhibitor, has broad and potent activity against hematological cancer cells.
-
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3). AMG 487 has potential to treat metastatic cancer.
-
MRT67307, a dual IKKε/TBK1 inhibitor, inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 blocks mTOR-dependent autophagy.
-
CCT020312, the G1/S checkpoint activator, is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.
-
SBI-0206965 is a selective and cell permeable autophagy kinase ULK1 inhibitor with IC50s of 108 nM for ULK1 and 711 nM for the highly related kinase ULK2 .
-
TPCA-1, a Direct Dual Inhibitor of STAT3 and NF-κB, Regresses Mutant EGFR-Associated NSCLC
2019-07-15
TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding. -
FGTI-2734 is a dual farnesyl and geranylgeranyl transferase-1 inhibitor. FGTI-2734 prevents membrane localization of KRAS and mutant KRAS pancreatic tumors.
-
CA-5f is a potent late-stage macroautophagy (autophagy) inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II and SQSTM1 protein.
-
BI-882370 is a potent RAF kinase inhibitor with IC50s of 0.4, 0.8, and 0.6 nM for oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases , respectively.
-
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions. MSX-122 has both anti-tumor and anti-metastasis activities.
-
ZT-12-037-01 is a ATP-competitive and specific STK19 inhibitor and inhibits oncogenic NRAS-driven melanocyte malignant transformation.
-
PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977 is a potential treatment for ccRCC and VHL disease.
-
BI-2852 is a potent KRAS inhibitor with nanomolar affinity and reduces pERK and pAKT levels in a dose-dependent manner in a KRAS mutant cell line NCI-H358.
-
BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1) and blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM.
-
WZ811 is an Orally Active CXCR4 Antagonist
2019-09-07
WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis. -
RU-302 is a pan-TAM inhibitor that blocks the TAM Ig1 ectodomain and the Gas6 Lg domain interaction. RU-302 blocks Gas6-inducible Axl receptor activation.
-
BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM.
-
IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction, and binds directly to uPAR with sub-micromolar affinity.
-
Vorolanib is an orally active, multikinase VEGF/PDGF receptor inhibitor with antitumor activity and is expected to disrupt tumor angiogenesis.
-
CCG-222740 is a potent and selective MRTF pathway inhibitor. It effectively reduces fibrosis in the skin and blocks melanoma metastasis.
-
AC-73 is a first specific, orally active the cluster of differentiation 147 (CD147) inhibitor and specifically disrupts CD147 dimerization.
-
UK 356618 is a Selective MMP-3 Inhibitor
2019-12-25
UK 356618 is a selective and potent inhibitor of MMP-3. UK 356618 exhibits potent anti-inflammatory and anti-cancer activity. -
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
GPP78 is a potent Nampt inhibitor. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells. GPP78 has anti-cancer and anti-tumor activity.
-
BAY-985 is an orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 and IKKε, respectively.
-
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
Balixafortide is a potent, selective peptidic CXCR4 antagonist with anti-cancer effects, and blocks β-arrestin recruitment and calcium flux.
-
CCT365623, an Orally Active LOX Inhibitor, Supresses EGFR (pY1068) and AKT Phosphorylation
2020-04-16
CCT365623 is an orally active LOX inhibitor, suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 has good pharmacokinetic properties. -
HM03 is a potent and selective HSPA5 inhibitor with anticancer activity. HSPA5 plays a key role in monitoring protein transport through the cell.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
GSK621 is a potent and specific AMPK activator and induces autophagy and apoptosis in acute myeloid leukemia (AML) cells.
-
EW-7195 is a potent and selective ALK5 inhibitor, and efficiently inhibits TGF-β1-induced Smad signaling, EMT and breast tumour metastasis to the lung.
-
CAY10404 is a potent and highly selective COX-2 inhibitor. CAY10404 is a potent inhibitor of PKB/Akt and MAPK signalling pathways.
-
SP-8356, an orally active CD147inhibitor, exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
Verucopeptin inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Also a potent HIF-1 inhibitor.
-
E7820, sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
-
Cyclo(-RGDfK) is a selective inhibitor of the αvβ3 integrin. Cyclo(-RGDfK) potently targets cancer cells through binding to the cell surface αvβ3 integrin.
-
Cilengitide is a compound targeting angiogenesis, the cornerstone of tumor growth and metastasis. ανβ3 and ανβ5 are the target of Cilengitide.
-
Tetrac inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.
-
BMS-P5 is an Orally Active PAD4 Inhibitor
2020-12-12
BMS-P5 is an orally active PAD4 inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model -
ML132, a potent and selective caspase 1 inhibitor with a unique selectivity pattern, is responsible for the proteolytic activation of IL-1β and IL-18.
-
ENMD-1198 is an orally active microtubule-targeting agent with antiproliferative and antiangiogenic activity.
-
CC-90001 is a potent, selective, and orally active inhibitor of JNK. CC-90001 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
YUM70 inhibits GRP78. Induces endoplasmic reticulum stress-mediated apoptosis. Pancreatic cancer. Acts as a novel anticancer agent.
-
FAPI-46 is a quinoline-based FAP-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation.
-
LYN-1604 is a Potent ULK1 Activator
2021-04-24
LYN-1604, a potent ULK1 activator, induces cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis. -
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist. SB-332235 inhibits acute and chronic models of arthritis in the rabbit.
-
ML339 is a Selective CXCR6 Antagonist
2021-05-12
ML339 is a small molecule antagonist would block Prostate cancer cell trafficking; hence mediate a metastatic event and disease progression. -
Butaprost is a selective prostaglandin E receptor (EP2) agonist. Butaprost can effectively mitigate kidney fibrogenesis in various fibrosis models.
-
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
Motesanib (AMG 706) is an orally active VEGFR inhibitor. Potently inhibits angiogenesis and induces regression in tumor xenografts.
-
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
Lumiracoxib is a COX-2 inhibitor. Lumiracoxib acts as nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities.
-
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with anti-cancer activity.
-
Ruxolitinib is a potent and selective JAK1/2 inhibitor and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy.
-
Nintedanib a potent and orally active triple vascular kinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
-
IMD-0354 is a Selective IKKβ Inhibitor
2021-11-09
IMD-0354 is a selective IKKβ inhibitor and potently inhibits NF-κB activity. IMD0354 has antitumor activity. -
Axitinib is a multi-targeted tyrosine kinase inhibitor and potently inhibitor VEGFR1, VEGFR2, VEGFR3 and PDGFRβ.
-
Spautin-1 is a specific and potent autophagy inhibitor which inhibits ubiquitin-specific peptidases, USP10 and USP13.
-
Alda-1 is a potent ALDH2 Agonist
2021-12-30
Alda-1 ameliorates H2O2-induced Achilles tendinopathy. Alda-1 could be used for preventing Achilles tendinopathy. -
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Zingerone is a natural orally active nontoxic methoxyphenol potent anti-inflammatory, antidiabetic, antioxidize, and anti-tumor properties.
-
Tanomastat is an orally active, non-peptidic biphenyl MMPs inhibitor, with antiangiogenic, anti-invasive and antimetastatic activities.
-
AUTAC2 is a FKBP12-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG and an SLF moiety.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Telatinib is an orally active inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit.
-
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs (Matrix metalloproteinases).
-
Vatalanib is an inhibitor of VEGFR2/KDR. Vatalanib induces inhibition of the angiogenic response to VEGF and PDGF.
-
Toceranib is a selective and orally active inhibitor of RTK and has the potential for the research of canine mast cell tumors.
-
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities.
-
KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
-
Pelecopan is a potent, selective, and orally active complement factor D inhibitor, possessing the potential to study paroxysmal nocturnal hemoglobinuria (PNH).
-
Certepetide is a Tumor-penetrating Enhancer via RGD Motif Interaction with Alphav-integrins
2022-09-01
Certepetide is a tumor-penetrating enhancer and has the potential for the research of metastatic pancreatic ductal adenocarcinoma. -
Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7.
-
Etrolizumab is a Gut-selective, Anti-β7 Integrin McAb for Inflammatory Bowel Disease (IBD) Research
2022-11-05
Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody and has the potential for the research of inflammatory bowel disease. -
ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
-
Coibamide A is an N-methyl-stabilized cytotoxic depsipeptide with antiproliferative activity. Coibamide A induces autophagosome accumulation.
-
Pegdinetanib (BMS-844203) is a selective VEGFR-2 inhibitor with antitumor activity.
-
Ruxolitinib is an orally-active JAK1/2 inhibitor. Ruxolitinib has the potential for the research of myeloproliferative neoplasm (MPN).
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Kits
-
Inhibitory Antibodies
-
Reference Standards
-
Induced Disease Models Products
-
GMP Small Molecules
-
Enzyme
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-17589 | Chloroquine phosphate |
Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
|
Pancreatic Cancer
Viral Infection
Parasitic Infection
Pain
SARS-CoV-2 Infection
Rheumatoid Arthritis
|
1344
|
| HY-17589A | Chloroquine |
Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
|
Breast Cancer
Pancreatic Cancer
Viral Infection
Parasitic Infection
Pain
SARS-CoV-2 Infection
Rheumatoid Arthritis
|
1344
|
| HY-D1056 | Lipopolysaccharides, from E. coli O55:B5 |
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be widely used to induce cellular inflammation and establish animal models related to inflammation.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use. Source: surface of Gram-negative bacteria |
|
616
|
| HY-11109 | Resatorvid |
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
|
|
536
|
| HY-12815A | MCC950 sodium |
MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
|
|
497
|
| HY-12815 | MCC950 |
MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
|
|
497
|
| HY-100381 | Nigericin sodium salt |
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.
Source: Streptomyces hygroscopicus |
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Bacterial Infection
Depression
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
258
|
| HY-127019 | Nigericin |
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC.
|
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Bacterial Infection
Depression
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
258
|
| HY-112879 | Mito-TEMPO |
Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke.
|
|
186
|
| HY-B2176 | ATP |
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
Source: widespread |
|
178
|
| HY-B0240 | Disulfiram |
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu2+ increases intracellular ROS levels and induces cuproptosis.
|
Metabolic or Endocrine Disease
Breast Cancer
Prostate Cancer
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Depression
Pain
Autoimmune Disease
Digestive System Inflammation
SARS-CoV-2 Infection
|
161
|
| HY-100573 | Necrosulfonamide |
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
|
Mixed Lineage Kinase
Necroptosis
Pyroptosis
Caspase
NOD-like Receptor (NLR)
Keap1-Nrf2
TNF Receptor
Interleukin Related
NO Synthase
Heme Oxygenase (HO)
Digestive System Disease
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Depression
Digestive System Inflammation
Cardiovascular Disease
Parkinson's Disease
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
147
|
| HY-13740 | Resiquimod |
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
|
Prostate Cancer
Viral Infection
Depression
Pain
Autoimmune Disease
SARS-CoV-2 Infection
Hepatitis C Virus Infection
|
120
|
| HY-B0673 | Pirfenidone |
Colorectal Cancer
Prostate Cancer
Viral Infection
Digestive System Inflammation
SARS-CoV-2 Infection
Lung Fibrosis
Rheumatoid Arthritis
|
96
|
|
| HY-W031727 | Hydroxychloroquine |
Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling.
|
|
95
|
| HY-14519 | Methotrexate |
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
|
|
87
|
| HY-L014 | NF-κB Signaling Compound Library |
Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.
MCE owns a unique collection of 1,801 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.
|
|
85
|
| HY-L078 | Gut Microbial Metabolite Library |
Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.
In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 475 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.
|
|
85
|
| HY-L046 | Anti-Cardiovascular Disease Compound Library |
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.
MCE supplies a unique collection of 2,468 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.
|
|
84
|
| HY-L114 | Anti-inflammatory Traditional Chinese Medicine Active Compound Library |
Inflammation promotes physiological and pathological processes by the activation of the immune system, local vascular system, and various cells within the damaged tissue. Accumulating epidemiological and clinical evidence shows that chronic inflammation is causally linked to various human diseases, including cerebrovascular, cardiovascular, joint, cutaneous, pulmonary, blood, liver, and intestinal diseases as well as diabetes.
Various natural products from Traditional Chinese Medicine (TCM) have been shown to safely suppress proinflammatory pathways and control inflammation-associated disease. MCE designs a unique collection of 1,665 Traditional Chinese Medicine active compounds with anti-inflammatory activity, which are derived from Coptis chinensis, Radix isatidis, Flos Lonicerae, Forsythia suspensa, etc. MCE Anti-inflammatory Traditional Chinese Medicine Active Compound Library is a useful tool for discovery anti-inflammatory drugs from TCM.
|
|
84
|
| HY-L034M | Anti-Aging Compound Library Mini |
Research has shown that drugs targeting aging pathways demonstrate promising potential in models of age-related diseases such as Alzheimer's disease, cardiovascular diseases, metabolic syndrome, osteoarthritis, and various malignancies. This suggests that intervening in the biological processes of aging may enable synergistic prevention and treatment of multiple chronic diseases. Against the backdrop of the gradual elucidation of core aging mechanisms-including cellular senescence, telomere attrition, epigenetic dysregulation, and chronic inflammation anti-aging research has shifted from traditional phenotypic interventions toward targeting key pathways that regulate biological age.
The MCE Anti-Aging Compound Library Mini is precisely built upon this cutting-edge concept. It focuses on aging-related targets validated through genetic or functional studies, comprising 381 compounds designed to provide systematic research tools for aging biology and intervention strategy development. The library covers core mechanisms such as mTOR, SIRT, energy metabolism, clearance of senescent cells, optimization of mitochondrial function, and telomere maintenance. For each target, 1-5 compounds with clear activity and strong representativeness have been carefully selected, spanning the entire translational spectrum from preclinical tool molecules to clinically investigational drugs.
|
|
83
|
| HY-L105S | Peptide Compound Library |
Peptides, composed of amino acids, serve as crucial building blocks for proteins and have gained significant attention in drug development over the past decade. The advancements in production, modification, and analytical technologies have led to a surge in the potential applications of peptides in medicine. Peptides offer a number of advantages over small molecule drugs, including: greater target specificity and efficacy, more predictable metabolic profiles, easier delivery to where they are needed in the body, and fewer side effects. Peptides are increasingly appearing in all branches of medicine as components of innovative drugs, imaging agents, diagnostic agents, and other complex drugs such as peptide-drug conjugates. To date, more than 80 peptide drugs have been approved to treat a variety of diseases, including microbial infections, obesity, anti-diabetes, and cancer, as well as to develop cell targeting platforms and improve cell penetration properties.
MCE designs a unique collection of 867 peptide compounds. HY-L105S is a peptide compound library that can be provided with solution form based on HY-L105, and can be applied to peptides-based drug development.
|
|
83
|
| HY-L133 | Cuproptosis Compound Library |
Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".
The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.
Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.
Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.
MCE supplies a unique collection of 446 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.
|
|
83
|
| HY-L156 | Autoimmune Disease Compound Library |
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).
MCE designs a unique collection of 1,040 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.
|
|
83
|
| HY-L164 | Serine/Threonine Kinase Inhibitor Library |
Protein serine/threonine kinases (PSKs) are protein kinases that use ATP as a high-energy donor molecule to transfer phosphate groups to serine/threonine residues of target protein. As an important signal transduction regulator, serine/threonine kinases can affect the function of target proteins by disrupting enzyme activity or binding of target proteins to other proteins. Serine/threonine kinases are involved in the regulation of immune response, cell proliferation, differentiation, apoptosis and other physiological processes. Serine/threonine kinase inhibitors are an important class of compounds that have been widely studied in cancer, chronic inflammation, autoimmune diseases, aging and other diseases.
MCE designs a unique collection of 2,276 serine/threonine kinase inhibitors, mainly targeting the receptor PKA, Akt, PKC, MAPK/ERK, etc, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases, anti-autoimmune diseases and anti-aging compounds.
|
|
83
|
| HY-L174 | Macrophage Related Compound Library |
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance.
MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L185 | Anti-Fibrosis Compound Library |
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.
MCE contains 2,568 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.
|
|
83
|
| HY-L210 | Anti-Rheumatic Arthritis Compound Library |
Rheumatoid Arthritis (RA) is a autoimmune disease characterized by persistent joint inflammation. The pathology of RA includes immune cell infiltration, synovial lining proliferation, pannus formation, and the destruction of joint cartilage and bone, which is highly disabling. Due to long-term chronic inflammation, RA not only severely affects the quality of life of patients but can also damage multiple organs, leading to lung diseases, cardiovascular diseases, and malignant tumors. The pathogenesis of RA is complex, involving genetic, environmental, and immune factors. With the advancement of high-throughput screening technology, screening for compounds targeting JAK, CCR, MEK, MMP targets may contribute to the development of more effective drugs against Rheumatoid Arthritis (RA).
MCE has collected 2,023 small molecule compounds with definite or potential anti-rheumatoid arthritis activity. This library is of significant value for researching the anti-RA drugs.
|
|
83
|
| HY-L214 | Liposome Library |
Liposomes are spherical or multilayered spherical vesicles formed by the self-assembly of diacyl chain phospholipids (lipid bilayers) in aqueous solutions, which can be made from natural or synthetic phospholipids and exhibit good biocompatibility and low toxicity. They can serve as delivery carriers for various bioactive substances (such as drugs, proteins, nucleic acids, etc.) and are widely used in biomedical and chemical research. The main advantages of liposomes include 1) Protective effect: Their bilayer structure can protect encapsulated molecules from enzymatic degradation, oxidation, and other influences, extending stability and activity; 2) Active targeting: Surface modifications enable active targeting, enhancing the concentration of drugs or molecules in specific tissues or cells; 3) Customizability: The composition and structure of liposomes can be adjusted according to needs, such as altering phospholipid types or adding targeting ligands. These properties make liposomes highly valuable in developing novel drug delivery systems, serving as nucleic acid carriers for gene transfection, studying cellular uptake mechanisms and drug release kinetics, as well as developing functional food additives to improve the bioavailability of nutritional components.
MCE contains 227 liposome compounds, which is a good tool for drug delivery-related studies.
|
|
83
|
| HY-L256 | Azide Compound Library |
In modern drug discovery and chemical biology research, the azide group (-N3) is an important functional moiety that is widely used in click chemistry, biomolecular labeling, drug delivery systems, and prodrug design due to its unique reactivity and bioorthogonality.
The MCE Azide Structural Compound Library contains 100 compounds featuring -N3 functional groups. It is designed for the construction of click chemistry reaction systems and the subsequent development of functional molecules. This library enables the rapid assembly of targeting ligands, linkers, and functional molecular modules, thereby accelerating PROTAC assembly, optimization of antibody-drug conjugate (ADC) linkers, and the development of biological labeling probes. In addition, the high reaction selectivity and excellent biocompatibility of the azide group allow it to maintain stable reactivity even in complex biological environments, improving controllability and efficiency in drug design. It serves as an indispensable molecular tool in modern medicinal chemistry and chemical biology research.
|
|
83
|
| HY-16569 | Colchicine |
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research.
|
Digestive System Disease
Lung Cancer
Prostate Cancer
Viral Infection
Coronavirus Infection
Depression
Pain
Autoimmune Disease
Digestive System Inflammation
Alzheimer's Disease
Lung Fibrosis
|
77
|
| HY-135748 | Polyinosinic-polycytidylic acid sodium |
Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis.
|
|
75
|
| HY-16141 | Cilengitide |
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
|
|
75
|
| HY-N0822 | Shikonin |
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Depression
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
74
|
| HY-107202 | Polyinosinic-polycytidylic acid |
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
|
RIG-I-like receptor (RLR)
Toll-like Receptor (TLR)
PKD
HSP
Bcl-2 Family
Interleukin Related
Apoptosis
Infection
Digestive System Disease
Prostate Cancer
Pain
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
73
|
| HY-A0003 | Lenalidomide |
Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
|
Molecular Glues
Ligands for E3 Ligase
IKZF Family
Casein Kinase
Apoptosis
Pyroptosis
MDM-2/p53
TNF Receptor
Inflammation or Immune System Disease
Renal Disease
Chronic Lymphocytic Leukemia
Diffuse Large B-cell Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Liver Failure
|
63
|
| HY-B0180 | Imiquimod |
|
62
|
|
| HY-13004 | Maraviroc |
Metabolic or Endocrine Disease
Pancreatic Cancer
Viral Infection
Digestive System Inflammation
SARS-CoV-2 Infection
Lung Fibrosis
Rheumatoid Arthritis
|
60
|
|
| HY-108841 | Raleukin |
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.
Species: Human |
|
57
|
| HY-B1081A | Oxidopamine hydrobromide |
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
|
Dopamine Receptor
Autophagy
Mitophagy
COX
PGE synthase
Interleukin Related
p38 MAPK
Apoptosis
Caspase
|
50
|
| HY-12497 | ANA-12 |
ANA-12 is a brain-penetrant, selective TrkB antagonist with IC50 values of 45.6 nM and 41.1 μM, and Kd values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory.
|
|
41
|
| HY-N0182 | Fisetin |
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
|
Digestive System Disease
Prostate Cancer
Viral Infection
Depression
Digestive System Inflammation
SARS-CoV-2 Infection
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
35
|
| HY-15418 | RS 504393 |
RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).
|
Cancer
Metabolic or Endocrine Disease
Digestive System Disease
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
33
|
| HY-P0023 | Cyclo(-RGDfK) |
|
32
|
|
| HY-50674 | INCB3344 |
INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.
|
Cancer
Metabolic or Endocrine Disease
Digestive System Disease
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
30
|
| HY-P9970 | Infliximab |
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47. Species: Human |
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
Lung Cancer
Breast Cancer
|
30
|
| HY-B0498 | Bindarit |
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity.
|
Cancer
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Digestive System Disease
Digestive System Inflammation
SARS-CoV-2 Infection
Lung Fibrosis
Rheumatoid Arthritis
|
29
|
| HY-12080 | BX471 |
Cancer
Metabolic or Endocrine Disease
Digestive System Disease
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
29
|
|
| HY-D0861A | EGTA tetrasodium |
EGTA tetrasodium is a cell-impermeant specific calcium ion chelator. EGTA tetrasodium has an apparent calcium dissociation constant (Kd) of 60.5 nM at physiological pH (7.4) and has very high specificity for Ca2+ over Mg2+ (Mg2+ Kd 1-10 mM). EGTA tetrasodium significantly inhibits the substrate adherence capacity of inflammatory macrophages.
|
|
28
|
| HY-18611A | Abaucin |
Cancer
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Digestive System Disease
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
28
|
|
| HY-D0861 | EGTA |
EGTA is a cell-impermeant specific calcium ion chelator. EGTA has an apparent calcium dissociation constant (Kd) of 60.5 nM at physiological pH (7.4) and has very high specificity for Ca2+ over Mg2+ (Mg2+ Kd 1-10 mM). EGTA significantly inhibits the substrate adherence capacity of inflammatory macrophages.
|
|
28
|
| HY-B0350A | Sodium butyrate |
Sodium butyrate ((Butanoic acid; Butyric acid) sodium) is an orally active HDAC inhibitor. Sodium butyrate induces hyperacetylation of core histones and affects phosphorylation of H1/H2A, thereby altering chromatin structure and regulating gene expression. Sodium butyrate can be used in research related to various cancers, inflammatory bowel disease, and sickle cell anemia.
|
|
28
|
| HY-153808 | Complete Freund's adjuvant (CFA) |
Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response.
|
|
25
|
| HY-P9908 | Adalimumab |
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
Species: Human |
|
20
|
| HY-100506 | GLPG0187 |
GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM. GLPG0187 inhibits migrasome biogenesis without cytotoxicity.
|
|
19
|
| HY-108847 | Etanercept |
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
|
|
16
|
| HY-13406 | TAK-779 |
Cancer
Metabolic or Endocrine Disease
Digestive System Disease
Viral Infection
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
13
|
|
| HY-P0278 | RGD |
RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
|
|
11
|
| HY-P3160 | Fibronectin |
Fibronectin, a glycoprotein present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans.
This product is a human Fibronectin obtained by recombinant expression in a rice expression system. |
|
11
|
| HY-P1740 | RGD peptide (GRGDNP) |
RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation.
|
|
10
|
| HY-P9926 | Dupilumab |
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.
Species: Human |
Inflammation or Immune System Disease
Breast Cancer
Non-Small Cell Lung Cancer
Staphylococcus Aureus Infection
|
9
|
| HY-107632 | GYY4137 |
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
|
8
|
| HY-W013636C | 2-Ketoglutaric acid potassium |
2-Ketoglutaric acid (Alpha-Ketoglutaric acid) (potassium) is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid potassium is a reversible and orally active inhibitor of tyrosinase with an IC50 value of 15 mM. 2-Ketoglutaric acid potassium also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid potassium significantly suppresses abnormal intestinal permeability, delocalization of tight junction proteins from the intestinal cells, expression of TNFα in vitro and in vivo. 2-Ketoglutaric acid potassium directly binds to TAK1, and inhibits the TRAF6-TAK1 interaction. 2-Ketoglutaric acid potassium also alleviates inflammatory bowel disease (IBD) symptoms and gut microbiota dysbiosis, evident by the improvements in the intestine length.
|
|
7
|
| HY-B1521 | Aluminum Hydroxide |
Aluminum Hydroxide is an orally active main form of aluminum used as adjuvant. Aluminum hydroxide-based adjuvant researches include the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway. Aluminum Hydroxide also acts as adjuvant to compensate low inherent immunogenicity of subunit vaccines.
|
|
7
|
| HY-108749 | Olive oil |
Olive oil (Cropure OL) is an oleaginous compound found in the fruit of the Olea europaea tree. Olive oil contains many phenolic components and exerts antioxidant activity. Olive oil exhibits hydroxyl radical scavenging, platelet aggregation inhibition and xanthine oxidase inhibitory activity. Olive oil can promote wound healing and relieve inflammation. Olive oil can be used for the research of inflammation, cancer, metabolic and cardiovascular disease, such as diabetic foot ulcers and inflammatory bowel disease.
|
Cancer
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
Inflammatory Bowel Disease
|
7
|
| HY-113224 | Desmosterol |
Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism . Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases .
|
Endogenous Metabolite
LXR
Fatty Acid Synthase (FASN)
Interleukin Related
Reactive Oxygen Species (ROS)
NOD-like Receptor (NLR)
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
Hepatitis C Virus Infection
|
6
|
| HY-W250978 | Ovalbumins |
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment. |
|
6
|
| HY-W018772 | D-Ribose(mixture of isomers) |
D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner.
|
|
5
|
| HY-N0573 | Umbelliferone |
Umbelliferone (7-Hydroxycoumarin), a natural orally active product of the coumarin family, is a fluorescing compound which can be used as a sunscreen agent. Umbelliferone induces cell cycle arrest, apoptosis and DNA fragmentation in HepG2 cells. Umbelliferone exhibits significant anticancer effects. Umbelliferone attenuates the alteration characteristics of allergic airway inflammation. Umbelliferone displays the neuroprotective effects and cross the blood-brain barrier. Umbelliferone exhibits anti-inflammatory and antioxidant effects in
chronic alcohol-fed rats.
|
|
5
|
| HY-14571 | E7820 |
E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a molecular glue that induces the targeted degradation of splicing factor RBM39 by recruiting the E3 ubiquitin ligase CUL4-RBX1-DDB1-DCAF15 (CRL4DCAF15). E7820 is an angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. E7820 can be used for the study of acute myeloid leukemia (AML).
|
|
5
|
| HY-P0240A | Tuftsin diacetate |
Tuftsin diacetate, a tetrapeptide, is a macrophage/microglial activator.
|
|
4
|
| HY-W011641 | (±)-Naringenin |
(±)-Naringenin is an orally available anti-inflammatory agent that can regulate both acute and chronic inflammation responses, while also showing antioxidant, neuroprotective, liver-protective, and anti-cancer effects. (±)-Naringenin promotes vasodilation in endothelial cells by activating BKCa channels in muscle cells. It also exerts protective effects against experimental colitis by inhibiting Toll-like receptor 4/NF-κB signaling, making it useful in studies related to sepsis, fulminant hepatitis, fibrosis, and cancer research.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Obesity
Rheumatoid Arthritis
|
4
|
| HY-P0240 | Tuftsin |
Tuftsin is a tetrapeptide. Tuftsin is a macrophage/microglial activator.
|
|
4
|
| HY-151435 | CCR6 antagonist 1 |
CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).
|
|
4
|
| HY-P9925 | Brodalumab |
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis.
Species: Human |
Digestive System Disease
Lung Cancer
Breast Cancer
Digestive System Inflammation
Crohn's Disease
Psoriasis
Rheumatoid Arthritis
|
4
|
| HY-137561 | Bexotegrast |
Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung.
|
|
4
|
| HY-Y0520 | Itaconic acid |
Itaconic acid, a precursor of polymers, chemicals, and fuels, can be synthesized by many fungi. Itaconic acid also is a macrophage-specific metabolite. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. Itaconic acid has anti-inflammatory, anti-microbial and immunomodulatory effect.
|
|
4
|
| HY-Y0850O | Polyvinyl alcohol (Mw 31000-50000, 87-89% hydrolyzed) |
Polyvinyl alcohol (PVA; Poly (Ethenol)) (Mw 31000-50000, 87-89% hydrolyzed) is a polymer with emulsifying and stabilizing properties, with a degree of hydrolysis of 87-89%. Polyvinyl alcohol (Mw 31000-50000, 87-89% hydrolyzed) mainly acts as a stabilizer in the preparation of nanomedicines; it not only maintains the structural integrity of PEGylated PLGA nanoparticles during double emulsion synthesis, but also facilitates the preparation of chitosan/matrine-PLGA nanoparticle aqueous solutions and lipid-polymer nanoparticles. Polyvinyl alcohol (Mw 31000-50000, 87-89% hydrolyzed) can be widely used in research related to fields such as breast cancer.
|
|
3
|
| HY-N5027 | Oxyberberine |
Oxyberberine (Oxyberberin; Berlambine) is an orally effective heme oxygenase HO-1 agonist that can activate antioxidant mechanisms by regulating the PI3K/Akt/AMPK signaling pathway. Oxyberberine induces HO-1 expression, increases SOD and GSH-Px activity, inhibits NF-κB-mediated inflammatory responses, and improves insulin sensitivity and glucose metabolism. Oxyberberine has anti-diabetic, neuroprotective, anti-inflammatory and antioxidant effects, and can be used to study type 2 diabetes, traumatic brain injury (TBI) and inflammatory bowel disease.
|
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Glucose Metabolism
Obesity
|
3
|
| HY-D0970 | Diphenyl Blue |
Diphenyl Blue (Trypan Blue) is a cell active dye, the most commonly used dye for the identification of dead cells, of en used to test cell membrane integrity and cell viability. Diphenyl Blue staining is one of the methods for tissue and cell culture. When cells are deactivated or have incomplete cell membranes, Diphenyl Blue can stain them Blue. Normal living cells with intact cell membranes reject Diphenyl blue and do not stain them blue. However, macrophages are capable of phagocytosis of Diphenyl Blue, so it can be used as a living stain for macrophages.
|
|
3
|
| HY-P9911 | Vedolizumab |
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Species: Human |
|
3
|
| HY-108910 | Chymotrypsin |
Chymotrypsin (EC 3.4.21.1; Chymotrypsin A) is an orally effective inhibitor targeting molecules such as TLR4, NF-κB, MMP-1, TNF-α, IL-1β, and IL-6. Chymotrypsin downregulates the TLR4/NF-κB signaling pathway, inhibiting the release of inflammatory factors, reducing cell infiltration and tissue damage. It also reduces the expression of tumor cell adhesion molecules (such as CD44 and CD54) and can be specifically detected by fluorescent probes (such as NBD-3). Chymotrypsin has anti-inflammatory, hepatoprotective, joint damage-reducing, liver protection against lipotoxicity, and anti-tumor metastasis functions. It can be used in research on diseases such as rheumatoid arthritis, non-alcoholic fatty liver disease, and melanoma metastasis. Chymotrypsin can be used in studies of inflammation, edema, and expectoration.
|
Breast Cancer
Digestive System Inflammation
Gastric Disease
Metastatic Melanoma
Pharyngitis
Rheumatoid Arthritis
|
3
|
| HY-N0577 | Apiin |
Apiin is a flavonoid glycoside-based iNOS inhibitor. Apiin inhibits the expression of inducible nitric oxide synthase in activated macrophages. Apiin exhibits anti-inflammatory activity.
|
|
2
|
| HY-P4846 | Ac-Pro-Gly-Pro-OH |
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a CXCR2 agonist. Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer.
|
|
2
|
| HY-N0671 | Rhapontin |
Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis.
|
Cancer
Metabolic or Endocrine Disease
Digestive System Disease
Depression
Digestive System Inflammation
Cardiovascular Disease
Lung Fibrosis
|
2
|
| HY-113011 | Maltotriose |
Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
|
|
2
|
| HY-P9984 | Etrolizumab |
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD).
Species: Human |
|
2
|
| HY-P99019 | Fremanezumab |
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine.
Species: Human |
|
2
|
| HY-P99550 | Tozorakimab |
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease.
Species: Human |
|
2
|
| HY-P10136 | IA9 |
IA9 (human TREM-2 182-190) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 can be used for neuroinflammation PET imaging. IA9 can be used for Rheumatoid arthritis (RA) and neuroinflammation research.
|
|
2
|
| HY-P2300 | Cyclo(Arg-Gly-Asp-D-Phe-Cys) |
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors.
|
|
2
|
| HY-P72717 | CD5L Protein, Mouse (HEK293, His) |
The CD5L protein is primarily expressed by macrophages and regulates inflammatory responses in infection or atherosclerosis. CD5L is incorporated into adipocytes via CD36-mediated endocytosis, thereby inhibiting lipid droplet size and affecting lipolysis. CD5L Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD5L protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Mouse; Source: HEK293 |
|
2
|
| HY-E70182 | Hyaluronidase 2 |
Hyaluronidase 2 (EC:3.2.1.35; HYAL2) is a hyaluronidase. Hyaluronidase 2 cleaves high-molecular-weight hyaluronan into intermediate, ~20 kDa, and tetrasaccharide fragments. Hyaluronidase 2 directly interacts with CD44 and ERM proteins, reduces CD44 hyaluronan binding capacity and ERM activation. Hyaluronidase 2 can be used for the research of gliomas, inflammatory bowel disease, congenital heart defects, heart failure.
|
|
1
|
| HY-P10935 | Amilo-5MER |
Amilo-5MER (5-MP) is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER is promising for research of autoimmune diseases and chronic inflammatory diseases.
|
|
1
|
| HY-P5522 | TriDAP |
TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1 agonist with a Kd value of 34.5 μM. TriDAP enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP decreases IκBα levels and increases p65 levels. TriDAP induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection.
|
|
1
|
| HY-P2171 | CCP peptide |
CCP peptide is a synthetic cyclic citrullinated peptide (CCP) and used as the substrate for detecting anti-CCP antibodies serologically. CCP peptide functions as a target for autoantibodies with a very high specificity for rheumatoid arthritis (RA).
|
|
1
|
| HY-13545 | ABT-510 |
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD).
|
|
1
|
| HY-P10935A | Amilo-5MER TFA |
Amilo-5MER (5-MP) TFA is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER TFA specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER TFA reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER TFA is promising for research of autoimmune diseases and chronic inflammatory diseases.
|
|
1
|
| HY-113434 | 5(S)-HETE |
5(S)-HETE is an endogenous metabolite present in Blood that can be used for the research of Rheumatoid Arthritis, Rhinitis and Asthma.
|
|
1
|
| HY-P2221 | Glepaglutide |
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease.
|
|
1
|
| HY-17490 | Oxaceprol |
Oxaceprol (N-Acetyl-L-hydroxyproline), an orally active derivative of L-proline, possesses distinct anti-inflammatory activity. Oxaceprol is usually used for the research of osteoarthritis and rheumatoid arthritis.
|
|
1
|
| HY-P990181 | Anti-Mouse myeloperoxidase/MPO Antibody (6G4) |
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is an anti-mouse myeloperoxidase/MPO IgG2c monoclonal antibody. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) can activate the cGAS/STING pathway. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) induces acute and chronic kidney injury in mice. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is often used in the construction of inflammation conditions models such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV).
Species: Mouse |
|
1
|
| HY-13545B | ABT-510 acetate |
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD).
|
|
1
|
| HY-P2221B | Glepaglutide acetate |
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease.
|
|
1
|
| HY-W014225 | 3-Phenoxybenzoic acid |
3-Phenoxybenzoic acid is the metabolite of pyrethroid insecticides. 3-Phenoxybenzoic acid induces immunotoxicity and oxidative stress, and inhibits the phagocytic ability of macrophages.
|
|
1
|
| HY-113358 | 6-keto Prostaglandin F1α |
6-keto Prostaglandin F1α is an endogenous metabolite present in Cerebrospinal_Fluid, Urine and Blood that can be used for the research of Meningitis, Rheumatoid Arthritis and Cardiopulmonary Resuscitation.
|
|
1
|
| HY-N5139 | Lecithins, egg |
Lecithins, egg (Lecithins, egg yolk; Belovo PL 85) is an orally active natural phospholipid mixture extracted from egg yolks. Lecithins, egg inhibits the activities of acetylcholinesterase (AChE) and angiotensin-converting enzyme (ACE). Lecithins, egg exhibits antibacterial, antioxidant and anti-inflammatory activities, and helps delay cellular senescence. Lecithins, egg enhances nerve conduction, improves memory and cognitive function, and exerts positive effects on delaying neurodegenerative diseases. Lecithins, egg promotes lipid absorption and alleviates diarrhea. Lecithins, egg acts as a high-efficiency drug carrier for the preparation of targeted drug delivery systems such as liposomes.
|
Digestive System Disease
Bacterial Infection
Neurodegenerative Disease
Oxidative Stress and Inflammation
Lipid Metabolism
|
1
|
| HY-P2171A | CCP peptide TFA |
CCP peptide TFA is a synthetic cyclic citrullinated peptide (CCP) and used as the substrate for detecting anti-CCP antibodies serologically. CCP peptide TFA functions as a target for autoantibodies with a very high specificity for rheumatoid arthritis (RA).
|
|
1
|
| HY-N2071 | Cedrol |
Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.
|
Environmental Pollutants
Fungal
Apoptosis
Platelet-activating Factor Receptor (PAFR)
Cytochrome P450
Caspase
Cancer
Digestive System Disease
Bacterial Infection
Fungal Infection
Digestive System Inflammation
Parkinson's Disease
|
1
|
| HY-P5623 | RVG |
RVG (RVG29) is a blood-brain barrier-permeable peptide derived from rabies virus glycoprotein, which binds to the α-7 subunit of neuronal nicotinic acetylcholine receptor (AchR). RVG efficiently delivers drugs to nerve cells and antigen-presenting cells in a targeted manner, and enhances the efficiency of antigen presentation and drug delivery.
|
|
1
|
| HY-W105750 | 6-Hydroxyhexanoic acid |
6-Hydroxyhexanoic acid (6-HHA) is a bacterial effector molecule with metabolic and immunomodulatory activities. 6-Hydroxyhexanoic acid activates the JAK1-STAT1 signaling pathway, promotes phenotypic conversion of M2 macrophages to M1 macrophages, and exerts anti-tumor effects by regulating macrophage polarization. 6-Hydroxyhexanoic acid inhibits lipolysis in adipocytes mediated by Gαi family GPCR, and reduces high-fat diet-induced weight gain and obesity. 6-Hydroxyhexanoic acid can be used in studies related to pancreatic ductal adenocarcinoma, obesity, and insulin resistance.
|
|
1
|
| HY-B0373 | Tiopronin |
Tiopronin is a diffusible antioxidant, an antidote to heavy metal poisoning and a radioprotective agent. Tiopronin can control the rate of cystine precipitation and excretion and has the potential for cystinuria, rheumatoid arthritis and hepatic disorders.
|
|
1
|
| HY-125527 | Resolvin D1 |
Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages.
|
|
1
|
| HY-P990297 | Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) |
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV.
Species: Human/Mouse/Rat |
|
1
|
| HY-P99673 | Itepekimab |
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD).
Species: Human |
|
1
|
| HY-P3719 | MOG(35-55) amide, mouse, rat |
MOG (35-55) amide, mouse, rat the terminal amidation form of the 35-55 fragment of the myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide (MOG (35-55) (HY-P1240)). MOG(35-55) amide, mouse, rat can be used for experimental autoimmune encephalomyelitis (EAE) modeling.
|
|
1
|
| HY-P990007 | Tulisokibart |
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.
Species: Human |
|
1
|
| HY-B0634S | Aceclofenac-d4 |
Aceclofenac-d4 is the deuterium labeled Aceclofenac. Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis.
|
|
/
|
| HY-184075S | Nomelcitinib |
Nomelcitinib is a TYK2 inhibitor that modulates the IL23 signaling pathway. Nomelcitinib is used for research on multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's disease, Sjögren's syndrome, and scleroderma.
|
Digestive System Disease
Digestive System Inflammation
Systemic Lupus Erythematosus
Multiple Sclerosis
Crohn's Disease
Psoriasis
Rheumatoid Arthritis
|
/
|
| HY-B0524AS | Betahistine-d3 dihydrochloride |
Betahistine-d3 (dihydrochloride) is the deuterium labeled Betahistine dihydrochloride. Betahistine dihydrochloride is an orally active histamine H1 receptor agonist and a H3 receptor antagonist. Betahistine dihydrochloride is used for the study of rheumatoid arthritis (RA).
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
/
|
| HY-121356S1 | Carebastine-d5 Methyl Ester |
Carebastine-d5 Methyl Ester is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner. Carebastine suppresses the expression of macrophage migration inhibitory factor.
|
|
/
|
| HY-121356S | Carebastine-d5 |
Carebastine-d5 is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner. Carebastine suppresses the expression of macrophage migration inhibitory factor.
|
|
/
|
| HY-166975 | Polysarcosine 100 |
Polysarcosine 100 (pSar 100) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 100 can be used in drug delivery research.
|
|
/
|
| HY-W127851 | CLA |
CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.
|
|
/
|
| HY-P10983 | LS10 |
LS10 can specifically bind to NG2 protein and is a functional ligand for targeted drug delivery to glioma. NG2 proteins are widely overexpressed in the glioma cells and restricted in normal tissue.
|
|
/
|
| HY-P991552 | AFM15 |
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD).
Species: Human |
|
/
|
| HY-D2279 | NFL-NH2 |
NFL-NH2 is a mitochondrial-targeted near-infrared ratiometric fluorescent probe. NFL-NH2 can rapidly detect NO levels associated with the inflammatory damage degree in rheumatoid arthritis (RA) mice models by ratiometric fluorescence imaging. The excitation wavelength and emission wavelength are 650 nm and 780 nm, respectively.
|
|
/
|
| HY-W753956 | Iminostilbene-d10 |
Iminostilbene-d10 is the deuterium labeled Iminostilbene (HY-N7064). Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases.
|
Isotope-Labeled Compounds
COX
HIF/HIF Prolyl-Hydroxylase
Pyruvate Kinase
TNF Receptor
Interleukin Related
STAT
NO Synthase
|
/
|
| HY-P10966 | Tat-IKIP (46-60) |
Tat-IKIP (46-60) is a IκB kinase (IKK)-targeting membrane-penetrating peptide. Tat-IKIP (46-60) inhibits IKK activation and NF-κB targeted gene expression by disrupting the IKKβ/NEMO complex. Tat-IKIP (46-60) significantly reduces DSS (HY-116282)-induced acute inflammation in inflammatory bowel disease (IBD) mice model and attenuates Zymosan-induced acute arthritis in acute arthritis model (AAM). Tat-IKIP (46-60) can be used for inflammatory diseases research, such as IBD, pancreatitis and rheumatoid arthritis.
|
|
/
|
| HY-N16735 | Isofouquierol |
Isofouquierol is a selective inhibitor targeting nitric oxide (NO) production with anti-inflammatory activity. Isofouquierol blocks NO overproduction by inhibiting the inducible nitric oxide synthase (iNOS)-related pathway. Isofouquierol can be used in the study of inflammation-related diseases (such as chronic inflammation, immune disorders).
|
|
/
|
| HY-P11354 | THR-123 |
THR-123 is an orally active ALK3 peptide agonist. THR-123 has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 suppresses inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 can be used for the study of kidney fibrosis.
|
|
/
|
| HY-117985BS | Evogliptin-d9 tartrate |
Evogliptin-d9 tartrate (DA-1229-d9 tartrate) is the deuterium labeled Evogliptin tartrate (HY-117985B). Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
|
|
/
|
| HY-B0174AS3 | Olsalazine-d6 |
Olsalazine-d6 is the deuterium labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.
|
|
/
|
| HY-B0174AS | Olsalazine-13C6 |
Olsalazine-13C6 is the 13C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.
|
|
/
|
| HY-P11101 | plCSA-BP |
plCSA-BP is a Placental CSA-binding peptide. plCSA-BP binds specifically to trophoblasts and not to other cell types in the placenta or to CSA-expressing cells in other tissues. plCSA-BP can guide nanoparticles for the targeted delivery of payloads (such as Indocyanine green (ICG) (HY-D0711) and Methotrexate (MTX) (HY-14519)) to the placenta, promising for placenta-specific drug delivery.
|
|
/
|
| HY-155884 | mPEG4000-amine |
mPEG4000-amine can be used to synthesize folate-conjugated polymer micelles for encapsulating anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
|
/
|
| HY-W583868S | 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE-d62 |
1-Palmitoyl-2-oleoyl-sn-glycero-3-PE-d62 (1,2-POPE-d62) is the deuterium labeled 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE (1,2-POPE; 16:0-18:1 PE) is a phosphatidylethanolamine (PE) lipid. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can induce lipid bilayer to form a hexagonal phase (HII) structure in an acidic environment and promote membrane fusion. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can enhance the endosomal escape ability of lipid nanoparticles (LNPs) and improve the cellular delivery efficiency of nucleic acid drugs such as mRNA. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can be used for LNP carrier targeting of gene therapy and mRNA vaccines.
|
|
/
|
| HY-W724397 | 3-Phenoxybenzoic acid-d9 |
3-Phenoxybenzoic acid-d9 (3-PBA-d9) is the deuterium labeled 3-Phenoxybenzoic acid (HY-W014225). 3-Phenoxybenzoic acid is the metabolite of pyrethroid insecticides. 3-Phenoxybenzoic acid induces immunotoxicity and oxidative stress, and inhibits the phagocytic ability of macrophages.
|
|
/
|
| HY-W766920 | Olsalazine Disodium-13C12 |
Olsalazine disodium-13C12 is the 13C-labeled Olsalazine disodium (HY-B0174). Olsalazine Disodium is an anti-inflammatory compound that works in inflammatory bowel disease and ulcerative colitis.
|
|
/
|
| HY-N18720 | Boswellia carterii extract |
|
/
|
|
| HY-P991927 | ZL-1201 |
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer.
Species: Human |
|
/
|
| HY-P991593 | ABT-147 |
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma.
Species: Human |
|
/
|
| HY-W1052178E | FA-PEG400-Cholesterol |
FA-PEG400-Cholesterol (Folate-PEG400-Cholesterol) is a multifunctional drug delivery system composed of Folic acid (HY-16637), polyethylene glycol (PEG), and Cholesterol (HY-N0322). Folic acid (FA) has a high affinity for folic acid receptors and can be used to target cell membrane receptors for drug delivery. Cholesterol can improve the circulation time of encapsulated drugs.
|
|
/
|
| HY-P11799 | cLABL |
cLABL is a cyclic peptide that specifically binds to ICAM‑1. cLABL mediates targeted enrichment and rapid endocytosis of nanoparticles. cLABL is applicable to researches such as precise drug delivery at inflammatory sites.
|
|
/
|
| HY-N20274 | Myrrh extract |
Myrrh extract (Commiphoramyrrha extract) is a myrrh (Commiphora myrrha) extract that can be used in research on inflammatory bowel disease.
|
|
/
|
| HY-P2792 | Beauveriolide III |
Beauveriolide III is an inhibitor of lipid droplet formation in mouse macrophages.
Source: Beauveria |
|
/
|
| HY-B0174AS2 | Olsalazine-d3,15N |
Olsalazine-d3,15N is 15N and deuterated labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.
|
|
/
|
| HY-D2925 | dTCOBG |
dTCOBG (dTCO-SNAP) is a SNAP-tag reactive benzylguanine (BG) analogue specifically designed for the specific labeling of immune cells. dTCOBG forms a stable thioether bond through the cysteine at the active site of SNAP-tag and O6-benzylguanine, resulting in a covalent linkage. dTCOBG demonstrates unique advantages in the labeling of macrophages derived from ER-HoxB8: it only labels SNAP-tag + macrophages, with no background signal in the control group. dTCOBG can be used for click chemistry labeling.
|
|
/
|
| HY-N6777S | Penicillic acid-13C8 |
Penicillic acid-13C8 is the 13C-labeled Penicillic acid (HY-N6777). Penicillic acid is a polyketide mycotoxin produced by several species of Aspergillus and Penicillium. Penicillic acid exhibits cytotoxicity in rat alveolar macrophages (AM) in vitro. Penicillic acid inhibits Fas ligand-induced apoptosis by blocking self-processing of caspase-8.
|
|
/
|
| HY-170231 | Bovine Osteopontin |
Bovine Osteopontin (OPN) is a secreted highly acidic calcium-binding phosphorylated glycoprotein that is chemotactic for macrophages, smooth muscle cells, endothelial cells, and glial cells.
|
|
/
|
| HY-P11029 | CES |
CES (CESPLLSEC) is a homing peptide targeting Synaptosomal associated protein 25 (SNAP25). CES specifically homes in intracranial U87MG and the WT-glioblastoma (GBM) model. CES can be used as a targeting peptide for drug delivery for cancers research.
|
|
/
|
| HY-I0447S | 4-Aminosalicylic acid-d6 |
4-Aminosalicylic acid-d6 is the deuterium labeled 4-Aminosalicylic acid (HY-I0447). 4-Aminosalicylic acid is an inhibitor for dihydrofolate reductase (DHFR) and an antituberculous agent. 4-Aminosalicylic acid exhibits anti-inflammatory activity and can be used in research of inflammatory bowel disease (IBD). 4-Aminosalicylic acid is orally active.
|
|
/
|
| HY-P10586 | Macrophage-activating lipopeptide 2 |
Macrophage-activating lipopeptide 2 (MALP-2) is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 can enhance endothelial nitric oxide synthase (eNOS) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 can enhance endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL).
|
|
/
|
| HY-159669 | Stercobilin hydrochloride (mixture of isomers) |
Stercobilin hydrochloride (amixture of isomers) is a bile pigment metabolized by gut bacteria, and it's also an HIV protease inhibitor, with a Ki of 4 μM. Stercobilin hydrochloride (a mixture of isomers) can induce pro-inflammatory activity in mouse macrophage RAW264 cells, including the production of TNF-α and IL-1β. Stercobilin hydrochloride (a mixture of isomers) can be used in studies of inflammation and viral infections.
|
|
/
|
| HY-P11038 | IL-23 cyclic peptide inhibitor 105 |
IL-23 cyclic peptide inhibitor 105, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 105 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research.
|
|
/
|
| HY-P991643 | MTRX1011A |
MTRX1011A is a humanized IgG1 monoclonal antibody inhibitor targeting CD4. MTRX1011A can be used for rheumatoid arthritis (RA) research.
Species: Human |
|
/
|
| HY-142140S | 3-epi-25-Hydroxy Vitamin D3-d6 |
3-epi-25-Hydroxy Vitamin D3-d6 is the deuterium labeled 3-epi-25-Hydroxy Vitamin D3 (HY-142140). 3-epi-25-Hydroxy Vitamin D3 is the vitamin D metabolite, while vitamin D metabolism highly dependent on macrophage polarization. The C3-epimerase pathway for vitamin D is active in macrophages.
|
|
/
|
| HY-W142432S | Perfluoroundecanoic acid-13C7 |
Perfluoroundecanoic acid-13C7 is the 13C-labeled Perfluoroundecanoic acid (HY-W142432). Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation.
|
|
/
|
| HY-D3197 | CDg16 |
CDg16 is a selective fluorescent dye targeting SLC18B1 (λabs/λem=458/544 nm) that is actively transported into lysosomal vesicles of activated macrophages independent of the endocytic pathway. CDg16 enables highly specific vesicle localization in live cells. CDg16 exhibits no cytotoxicity and accurately distinguishes activated M1 and M2 subsets from different origins. CDg16 shows low background staining in non-activated cells and normal organs, making it suitable for time-lapse imaging. In preclinical animal models of inflammatory sites, atherosclerotic plaques and liver inflammation, CDg16 allows visualization of activated macrophages. CDg16 can be used to study inflammation-related diseases and atherosclerosis.
|
|
/
|
| HY-P11650 | HE4-1 leech peptide |
HE4-1 leech peptide is a p38 MAPK inhibitor with an additional c-Jun N-terminal kinase (JNK) inhibitory role. HE4-1 leech peptide suppresses macrophage migration, and does not significantly affect macrophage immunological activities including phagocytic ability, lysozyme activity, and expression levels of most inflammatory factors. HE4-1 leech peptide can be used for the research of atherosclerosis.
|
|
/
|
| HY-D2978 | MR2-cy5 |
MR2-cy5 is a fluorescent agent. MR2-cy5 is highly specific to CD206. MR2-cy5 can track CD206+ macrophages.
|
|
/
|
| HY-166973 | Polysarcosine 20 |
Polysarcosine 20 (pSar 20) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 20 can be used in drug delivery research.
|
|
/
|
| HY-175310S | Voderdeucitinib |
Voderdeucitinib (Compoudn I) is a TYK2 inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD).
|
|
/
|
| HY-17623S | Tegoprazan-d6 |
Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases.
|
|
/
|
| HY-126675G | AS2863619 (GMP) |
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4+ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects.
|
|
/
|
| HY-P4802 | Pam3-Cys-Ala-Gly |
Pam3-Cys-Ala-Gly, a synthetic bacterial lipopeptide, is a potent macrophage and B cell activator.
|
|
/
|
| HY-N22062 | Microencapsulated flaxseed oil powder |
Microencapsulated flaxseed oil powder is a functional ingredient. Microencapsulated flaxseed oil powder can be used in a variety of food formulations to enhance nutritional value by increasing ω-3 fatty acid content without adversely affecting sensory properties. ω-3 fatty acids are considered beneficial in preventing a variety of systemic diseases and syndromes, including coronary heart disease, hypertension, hypercholesterolemia, cancer, inflammatory bowel disease, diabetes, and neurodegenerative diseases. |
Neurodegenerative Disease
Type 1 Diabetes
Inflammatory Bowel Disease
Hypertension
Type 2 Diabetes
Hypercholesterolemia
|
/
|
| HY-W1052178 | FA-PEG2000-Cholesterol |
FA-PEG2000-Cholesterol (Folate-PEG2000-Cholesterol) is a multifunctional drug delivery system composed of Folic acid (HY-16637), polyethylene glycol (PEG), and Cholesterol (HY-N0322). Folic acid (FA) has a high affinity for folic acid receptors and can be used to target cell membrane receptors for drug delivery. Cholesterol can improve the circulation time of encapsulated drugs.
|
|
/
|
| HY-D3410 | CDr17 |
CDr17 is a GLUT1 substrate and selective fluorescent dye staining M1 microphages. CDr17 utilizes the Gating-Oriented Live-cell Distinction (GOLD) mechanism to enter M1 macrophages (Ex/Em = 646/662 nm).
|
|
/
|
| HY-P10911 | IETP2 |
IETP2 targets low-density lipoprotein receptor-related protein 1 (LRP1) with a KD of 738 nM and can be used for drug- and imaging agents delivery across the blood-labyrinth barrier (BLB).
|
|
/
|
| HY-W1052178C | FA-PEG10000-Cholesterol |
FA-PEG10000-Cholesterol (Folate-PEG10000-Cholesterol) is a multifunctional drug delivery system composed of Folic acid (HY-16637), polyethylene glycol (PEG), and Cholesterol (HY-N0322). Folic acid (FA) has a high affinity for folic acid receptors and can be used to target cell membrane receptors for drug delivery. Cholesterol can improve the circulation time of encapsulated drugs.
|
|
/
|
| HY-P11296 | LLVK |
LLVK is a selective IκB phosphorylation inhibitor. LLVK reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). LLVK is promising for research of inflammatory bowel disease and rheumatoid arthritis.
|
|
/
|
| HY-W1052178B | FA-PEG5000-Cholesterol |
FA-PEG5000-Cholesterol (Folate-PEG5000-Cholesterol) is a multifunctional drug delivery system composed of Folic acid (HY-16637), polyethylene glycol (PEG), and Cholesterol (HY-N0322). Folic acid (FA) has a high affinity for folic acid receptors and can be used to target cell membrane receptors for drug delivery. Cholesterol can improve the circulation time of encapsulated drugs.
|
|
/
|
| HY-184529 | 5-TAMRA-LQIQSWSSSPC-Mal-PEG2000-DSPE |
5-TAMRA-LQIQSWSSSP-PEG2000-DSPE is a PEG compound labeled with the fluorescent group 5-TAMRA. 5-TAMRA-LQIQSWSSSP-PEG2000-DSPE is commonly used to construct targeted liposomes, LNPs (lipid nanoparticles), micelles, or nanomedicine delivery systems.
|
|
/
|
| HY-N17131 | 24-O-Acetyllycoclavanol |
24-O-Acetyllycoclavanol (compound 1) is a triterpenoid anti-inflammatory agent that selectively targets the NF-κB and ERK1/2 signaling pathways. It exerts its anti-inflammatory activity by inhibiting lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS) and COX-2 expression, reducing the production of inflammatory mediators such as nitric oxide (NO), IL-1β, and IL-8. 24-O-Acetyllycoclavanol can be used in research related to inflammatory bowel disease (IBD). 24-O-Acetyllycoclavanol can be biologically isolated from the ethyl acetate extract of Lycopodium clavatum.
|
|
/
|
| HY-N16408 | Berkeleyamide B |
Berkeleyamide B is a dual matrix metalloproteinase-3 (MMP-3) and caspase-1 inhibitor. Berkeleyamide B is promising for research of cancers and inflammatory disease (e.g., rheumatoid arthritis).
Source: Penicillium rubrum |
|
/
|
| HY-N10664 | Piperlactam S |
Piperlactam S is an active compound. Piperlactam S can be isolated from Piper kadsura. Piperlactam S can be used for the research of chronic inflammation.
|
|
/
|
| HY-W1052178A | FA-PEG3400-Cholesterol |
FA-PEG3400-Cholesterol (Folate-PEG3400-Cholesterol) is a multifunctional drug delivery system composed of Folic acid (HY-16637), polyethylene glycol (PEG), and Cholesterol (HY-N0322). Folic acid (FA) has a high affinity for folic acid receptors and can be used to target cell membrane receptors for drug delivery. Cholesterol can improve the circulation time of encapsulated drugs.
|
|
/
|
| HY-P991612 | S095024 |
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies.
Species: Human |
|
/
|
| HY-W1052178D | FA-PEG1000-Cholesterol |
FA-PEG1000-Cholesterol (Folate-PEG1000-Cholesterol) is a multifunctional drug delivery system composed of Folic acid (HY-16637), polyethylene glycol (PEG), and Cholesterol (HY-N0322). Folic acid (FA) has a high affinity for folic acid receptors and can be used to target cell membrane receptors for drug delivery. Cholesterol can improve the circulation time of encapsulated drugs.
|
|
/
|
| HY-P991591 | MOR101 |
MOR101 is a humanized monoclonal antibody inhibitor targeting ICAM-1/CD54. MOR101 can be used to study acute and chronic inflammation, such as burns.
Species: Human |
|
/
|
| HY-166974 | Polysarcosine 150 |
Polysarcosine 150 (pSar 150) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 150 can be used in drug delivery research.
|
|
/
|
| HY-P2642 | Peptide 78 |
Peptide 78, a chemotactic cytokine, a 78 amino acid protein member of the IL-8 or C-X-C chemokine supergene family. ENA-78 plays an important role in the elicitation of predominantly neutrophils (PMNs) into the joints of rheumatoid arthritis (RA).
|
|
/
|
| HY-P11208 | mNLS-CPP-WSTF |
mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
|
|
/
|
| HY-P11452 | (KKEEE)3K |
(KKEEE)3K is a kidney-targeting peptide. (KKEEE)3K enters renal tubular cells via megalin receptor-mediated endocytosis. (KKEEE)3K can be used in the research of renal drug delivery.
|
|
/
|
| HY-D3190 | BODIPY−DOX |
BODIPY-DOX is a conjugate composed of BODIPY and Doxorubicin (HY-15142A), as well as a pH-activated fluorescent probe for M1 macrophages and an apoptosis inducer. BODIPY-DOX undergoes pH-induced hydrazone bond cleavage in acidic M1 macrophage phagosomes, thereby releasing cytotoxic Doxorubicin (Dox) and inhibiting the function of pro-inflammatory M1 macrophages. BODIPY-DOX highly selectively inhibits the production of relevant pro-inflammatory cytokines by mouse and human monocyte-derived M1 macrophages, while exerting minimal effects on M2 or unactivated macrophages. Therefore, BODIPY-DOX enables simultaneous fluorescent tracing, differentiation and elimination of specific macrophage subsets, and exhibits the potential to regulate tissue regeneration in zebrafish models.
|
|
/
|
| HY-N9346 | Phlorigidoside C |
Phlorigidoside C, a natural iridoid glucoside, possesses anti-rheumatoid arthritis effect.
|
|
/
|
| HY-W744235 | Levofloxacin-d3 sodium |
Levofloxacin-d3 sodium is the deuterium labeled Levofloxacin sodium (HY-B0330C). Levofloxacin ((-)-Ofloxacin) sodium is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin sodium inhibits the DNA gyrase and topoisomerase IV. Levofloxacin sodium can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin sodium shows anti-orthopoxvirus activity.
|
|
/
|
| HY-178762S | RIPK1-IN-35 |
RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC50 of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C)-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis.
|
|
/
|
| HY-D2480 | BODIPY 480/508-cholesteryl linoleate |
BODIPY 480/508-cholesteryl linoleate is a cell-permeable and fluorescently tagged derivative of Cholesteryl Linoleate (HY-W010697). BODIPY 480/508-cholesteryl linoleate has been used to monitor cholesterol trafficking in isolated human monocyte-derived macrophages (Ex/Em=480/508 nm).
|
|
/
|
| HY-N0444R | Rubiadin (Standard) |
Rubiadin (Standard) is the analytical standard of Rubiadin (HY-N0444). This product is intended for research and analytical applications. Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections.
|
Cancer
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
/
|
| HY-P992331 | CEL383 |
CEL383 is a human monoclonal antibody targeting TREM1. CEL383 blocks the TREM1 signaling pathway, thereby alleviating inflammation and reducing the levels of inflammatory mediators. CEL383 can be used in research related to inflammatory bowel disease.
Species: Human |
|
/
|
| HY-113011R | Maltotriose (Standard) |
Maltotriose (Standard) is the analytical standard of Maltotriose (HY-13011). This product is intended for research and analytical applications. Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
|
|
/
|
| HY-121246S | Fluorofenidone-d3 |
Fluorofenidone-d3 (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC).
|
|
/
|
| HY-N12243 | Kopsininic acid |
Kopsininic acid is a natural product derived from Kopsia hainanensis. Kopsininic acid can be used in the research of rheumatoid arthritis, pharyngitis, tonsillitis and edema.
|
|
/
|
| HY-B0330BS1 | Levofloxacin-d3 hydrochloride |
Levofloxacin-d3 ((-)-Ofloxacin-d3) hydrochlorideis deuterium labeled Levofloxacin (hydrochloride). Levofloxacin ((-)-Ofloxacin) hydrochloride is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride inhibits the DNA gyrase and topoisomerase IV. Levofloxacin hydrochloride can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrochloride shows anti-orthopoxvirus activity.
|
|
/
|
| HY-126855S | Cholic acid 7-sulfate-d4 |
Cholic acid 7-sulfate-d4 (7-Sulfocholic acid-d4) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation.
|
|
/
|
| HY-B0493S | Niflumic Acid-d5 |
Niflumic Acid-d5 is the deuterium labeled Niflumic acid. Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
|
|
/
|
| HY-121351 | Inokosterone |
Inokosterone is a potential agent target of estrogen receptor 1 in rheumatoid arthritis patients.
|
|
/
|
| HY-N16435 | Plumericin |
Plumericin is an anti-inflammatory, antioxidant, and antibacterial agent. Plumericin reduces Apoptosis, promotes Nrf-2 and inhibits NF-κB and AhR activation, blocks STAT3 signaling. Plumericin inhibits Mycobacterium tuberculosis growth. Plumericin can be used for the research of chronic kidney disease, vascular diseases, inflammatory bowel diseases, peritonitis, and tuberculosis.
|
Digestive System Disease
Cardiovascular Disease
Renal Disease
Mycobacterium Tuberculosis Infection
Colitis
|
/
|
| HY-17490R | Oxaceprol (Standard) |
Oxaceprol (Standard) is the analytical standard of Oxaceprol. This product is intended for research and analytical applications. Oxaceprol (N-Acetyl-L-hydroxyproline), an orally active derivative of L-proline, possesses distinct anti-inflammatory activity. Oxaceprol is usually used for the research of osteoarthritis and rheumatoid arthritis.
|
|
/
|
| HY-117985S | Evogliptin-d9 |
Evogliptin-d9 (DA-1229-d9) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
|
|
/
|
| HY-164893 | ABBV-154 |
ABBV-154 is an anti-TNF antibody-drug conjugate (ADC). ABBV-154 is composed of the humanized antibody Adalimumab (HY-P9908) conjugated with a glucocorticoid receptor modulator (HY-137883). ABBV-154 can be used in studies of rheumatoid arthritis, Crohn's disease and polymyalgia rheumatica.
|
|
/
|
| HY-40421 | (R)-3-Fluoropyrrolidine hydrochloride |
(R)-3-Fluoropyrrolidine hydrochloride is an intermediate. (R)-3-Fluoropyrrolidine hydrochloride can be used in the synthesis of hVanin-1 inhibitor (Compound X20). (R)-3-Fluoropyrrolidine hydrochloride can be used in the research of inflammatory bowel disease.
|
|
/
|
| HY-P992073 | OpSCF |
OpSCF (INS1148) is an antibody that specifically binds and inactivates inflammatory stem cell factor (SCF), blocks the positive feedback cycle of chronic inflammation, and aids tissue repair. OpSCF can be used for research related to asthma, pulmonary fibrosis, and interstitial lung disease.
Species: Human |
|
/
|
| HY-P10889 | CNI103 |
CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (KD=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases.
|
|
/
|
| HY-P991439 | BIIB023 |
BIIB023 is a human monoclonal antibody (mAb) targeting TNFRSF12A/TWEAKR/CD266. BIIB023 can be used in lupus nephritis and rheumatoid arthritis research.
Species: Human |
|
/
|
| HY-W014225S | 3-Phenoxybenzoic acid-13C6 |
3-Phenoxybenzoic acid-13C6 is the 13C6 labeled 3-Phenoxybenzoic acid. 3-Phenoxybenzoic acid is the metabolite of pyrethroid insecticides. 3-Phenoxybenzoic acid induces immunotoxicity and oxidative stress, and inhibits the phagocytic ability of macrophages.
|
|
/
|
| HY-B0524AS1 | Betahistine-13C,d3 dihydrochloride |
Betahistine-13C,d3 (dihydrochloride) is the 13C- and deuterium labeled Betahistine (dihydrochloride). Betahistine dihydrochloride is an orally active histamine H1 receptor agonist and a H3 receptor antagonist. Betahistine dihydrochloride is used for the study of rheumatoid arthritis (RA).
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
/
|
| HY-P5352 | Hyaluronan-IN-1 |
Hyaluronan-IN-1 (Pep-1) is a Hyaluronan inhibitor with a Kd value of 1.65 μM. Hyaluronan-IN-1 blocks CD44-dependent cell adhesion. Hyaluronan-IN-1 inhibits cell adhesion to hyaluronan substrates. Hyaluronan-IN-1 suppresses the development of contact hypersensitivity in mice by blocking the homing process of inflammatory cells to the skin. Hyaluronan-IN-1 also inhibits responses during the sensitization phase. Hyaluronan-IN-1 reduces lung metastasis of melanoma and prolongs the survival of mice. Hyaluronan-IN-1 can be used in research related to contact hypersensitivity, chronic skin inflammation, and melanoma.
|
|
/
|
| HY-D1056B2 | Lipopolysaccharides, from Proteus mirabilis |
Lipopolysaccharides, from Proteus mirabilis are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus mirabilis, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus mirabilis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Proteus mirabilis is a major pathogen causing urinary tract infections and may also contribute to rheumatoid arthritis. Lipopolysaccharides, from Proteus mirabilis also exhibit potential anti-tumor effects, demonstrating in vivo inhibitory activity against solid tumors such as meningosarcoma and Walker carcinosarcoma.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use. |
|
/
|
| HY-18342S | Diflunisal-d3 |
Diflunisal-d3 is the deuterium labeled Diflunisal. Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (COX) Inhibitor.
|
|
/
|
| HY-129959 | Aluminum phthalocyanine chloride |
Aluminum phthalocyanine chloride is a photosensitizer that effectively inhibits the parasite Leishmania amazonensis (the causative agent of cutaneous leishmaniasis) by light-mediated cytolysis. Aluminum phthalocyanine chloride causes parasite morphology and cytolysis of isolated amasilians, while higher photosensitizer concentrations and light intensities are required to induce lysis of mammalian cells. Aluminum phthalocyanine chloride lyses parasites within infected J774 macrophages and can be used to further investigate the study of leishmaniasis.
|
|
/
|
| HY-17479BS | Amfenac-d5 sodium |
Amfenac-d5 sodium is deuterated-labeled Amfenac sodium. Amfenac Sodium is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac Sodium can be used for the research of acute and chronic inflammation.
|
|
/
|
| HY-13010S | Laquinimod-d5 |
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research.
|
|
/
|
| HY-17479S | Amfenac-d5 |
Amfenac-d5 is the deuterium labeled Amfenac. Amfenac is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac can be used for the research of acute and chronic inflammation.
|
|
/
|
| HY-P990237 | Anti-Mouse ICOS Antibody (7E.17G9) |
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer.
Species: Mouse |
|
/
|
| HY-W740611 | Trihydroxycoprostane |
Trihydroxycoprostane (THCP) is a polyhydroxysterane compound with a 5β configuration. ITrihydroxycoprostane acts as a key intermediate in the biosynthesis of bile acids from cholesterol and also serves as an important sterol metabolite generated by host-gut microbiota interactions. Trihydroxycoprostane can be used for mechanistic studies of diseases such as non-alcoholic fatty liver disease, inflammatory bowel disease, and bile acid metabolism disorders.
|
|
/
|
| HY-100573S | Necrosulfonamide-d4 |
Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
|
Isotope-Labeled Compounds
Mixed Lineage Kinase
Necroptosis
Pyroptosis
Caspase
NOD-like Receptor (NLR)
Keap1-Nrf2
TNF Receptor
Integrin
NO Synthase
Heme Oxygenase (HO)
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-P991217 | EU-103 |
EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10−7 and 10−9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer.
Species: Human |
|
/
|
| HY-P11208C | mNLS-CPP-WSTF TFA |
mNLS-CPP-WSTF TFA is the trifluoroacetate salt of mNLS-CPP-WSTF (HY-P11208). mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
|
|
/
|
| HY-P991401 | GSK2862277 |
GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc.
Species: Human |
|
/
|
| HY-B0493S1 | Niflumic acid-13C6 |
Niflumic acid-13C6 is the 13C6 labeled Niflumic acid. Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
|
|
/
|
| HY-N0586 | Norisoboldine |
Norisoboldine is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis.
|
|
/
|
| HY-P99704 | Licaminlimab |
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation.
Species: Human |
|
/
|
| HY-W115607 | PEG4000-bis-amine |
PEG4000-bis-amine (Poly(ethylene glycol)-bis-amine 4000) is a diamine-terminated polyethylene glycol that acts as a linker for conjugate synthesis. PEG4000-bis-amine facilitates the development of MUC1 aptamer-based near-infrared fluorescent probes, and also conjugates folic acid with the near-infrared dye ICG-Der-01 to form a tumor-targeting probe. PEG4000-bis-amine supports the synthesis of folic acid-PEG-DSPE conjugates for the preparation of folic acid-targeted biliposomes. PEG4000-bis-amine is widely used in studies related to breast cancer, non-small cell lung cancer, hepatocellular carcinoma, rheumatoid arthritis, and tumors with high folate receptor expression.
|
|
/
|
| HY-122357 | Bestim |
Bestim (γ-Glu-Trp) is a dipeptide, which exhibits high affinity to murine peritoneal macrophages, thymocytes, and plasma membranes isolated from these cells, with Kds of 3.1, 2.1, 18.6 and 16.7 nM, respectively. Bestim inhibits adenylate cyclase in the membranes of murine macrophages and thymocytes. Bestim exhibits immunomodulatory efficacy.
|
|
/
|
| HY-B0373S1 | Tiopronin-d3 |
Tiopronin-d3 is the deuterium labeled Tiopronin. Tiopronin is a diffusible antioxidant, an antidote to heavy metal poisoning and a radioprotective agent. Tiopronin can control the rate of cystine precipitation and excretion and has the potential for cystinuria, rheumatoid arthritis and hepatic disorders.
|
|
/
|
| HY-P990723 | Timdarpacept |
Timdarpacept (DNL310) is a recombinant SIRPa-Fc fusion protein that can activate macrophages to enhance anti-tumor activity by blocking CD47-SIRPa.
Species: Human |
|
/
|
| HY-P99642 | Gimsilumab |
Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA).
Species: Human |
|
/
|
| HY-P99307 | Namilumab |
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis.
Species: Human |
|
/
|
| HY-P10449 | M2 Peptide |
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis.
|
|
/
|
| HY-N3196 | Neotuberostemonine |
Neotuberostemonine, one of the main antitussive alkaloids in the root of Stemona tuberosa Lour, attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages.
|
|
/
|
| HY-P11107 | RP-832c |
RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF).
|
|
/
|
| HY-P991181 | VTX-1218 |
VTX-1218 is a VSIG4 inhibitor with human Kd 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types.
Species: Human |
|
/
|
| HY-P11354A | THR-123 TFA |
THR-123 TFA is an orally active ALK3 peptide agonist. THR-123 TFA has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 TFA suppresses inflammation, Apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 TFA can be used for the study of kidney fibrosis.
|
|
/
|
| HY-P11296A | LLVK TFA |
LLVK TFA is a selective IκB phosphorylation inhibitor. LLVK TFA reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). LLVK TFA is promising for research of inflammatory bowel disease and rheumatoid arthritis.
|
|
/
|
| HY-W011927R | 4,4'-Sulfonyldiphenol (Standard) |
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone) (Standard) is the analytical standard of 4,4'-Sulfonyldiphenol (HY-W011927). This product is intended for research and analytical applications. 4,4'-Sulfonyldiphenol, a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
|
Reference Standards
Estrogen Receptor/ERR
Histone Methyltransferase
Thyroid Hormone Receptor
PI3K
Akt
mTOR
Androgen Receptor
Drug Derivative
Cancer
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-P990735 | Donzakimig |
Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G4S)2 linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions.
Species: Human |
|
/
|
| HY-N0573S | Umbelliferone-d5 |
Umbelliferone-d5 (7-Hydroxycoumarin-d5) is the deuterium labeled Umbelliferone (HY-N0573 ). Umbelliferone (7-Hydroxycoumarin), a natural orally active product of the coumarin family, is a fluorescing compound which can be used as a sunscreen agent. Umbelliferone induces cell cycle arrest, apoptosis and DNA fragmentation in HepG2 cells. Umbelliferone exhibits significant anticancer effects. Umbelliferone attenuates the alteration characteristics of allergic airway inflammation. Umbelliferone displays the neuroprotective effects and cross the blood-brain barrier. Umbelliferone exhibits anti-inflammatory and antioxidant effects in chronic alcohol-fed rats.
|
|
/
|
| HY-125527S | Resolvin D1-d5 |
Resolvin D1-d5 is the deuterium labeled Resolvin D1. Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α-mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages.
|
|
/
|
| HY-P3499 | Dolcanatide |
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research.
|
|
/
|
| HY-P99375 | Narnatumab |
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer.
Species: Human |
|
/
|
| HY-W018772R | D-Ribose(mixture of isomers) (Standard) |
D-Ribose(mixture of isomers) (Standard) is the analytical standard of D-Ribose(mixture of isomers). This product is intended for research and analytical applications. D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner.
|
|
/
|
| HY-P99746 | Murlentamab |
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming.
Species: Human |
|
/
|
| HY-P99198 | Fletikumab |
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis.
Species: Human |
|
/
|
| HY-W250121 | Tragacanth gum |
Tragacanth gum is an orally active anionic composite polysaccharide and multifunctional biomaterial. Tragacanth gum exhibits biocompatibility, mucoadhesion and renoprotective effects, and effectively promotes wound closure and tissue healing. Tragacanth gum can be isolated from Astragalus gummifer. Tragacanth gum acts as an emulsifier and drug delivery carrier, and is also widely used in fields such as 3D scaffolds, tissue engineering and green nanoparticle preparation. High doses of Tragacanth gum may induce reversible forestomach squamous epithelial hyperplasia in mice, but show no mutagenic or carcinogenic activity. Tragacanth gum is commonly used in studies related to diseases including systemic candidiasis, rheumatoid arthritis and osteosarcoma.
|
|
/
|
| HY-P99779 | Plonmarlimab |
Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19.
Species: Human |
|
/
|
| HY-W018772S15 | D-Ribose(mixture of isomers)-13C5 |
D-Ribose(mixture of isomers)-13C5 isomers)-13C5 is the 13C labeled D-Ribose(mixture of isomers). D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner.
|
|
/
|
| HY-P991138 | Firsekibart |
Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease.
Species: Human |
|
/
|
| HY-N0586A | Norisoboldine hydrochloride |
Norisoboldine hydrochloride is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine hydrochloride, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis.
|
|
/
|
| HY-P99184 | Abrilumab |
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD).
Species: Human |
|
/
|
| HY-P990061 | Polzastobart |
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody and LILRB2 (ILT4) antagonist. Polzastobart specifically binds to and antagonizes LILRB2, relieves ILT4-mediated myeloid immunosuppression, and promotes the polarization of macrophages from an M2-like phenotype to an M1-like phenotype. Polzastobart induces macrophage polarization, IFNγ signaling, and T cell inflammation-related pharmacodynamic responses in ex vivo human renal cancer, lung cancer, and head and neck cancer tissues. Polzastobart can be used in studies related to tumor-associated macrophages and tumor immunity. For the isotype control of Polzastobart, refer to: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Species: Human |
|
/
|
| HY-N0444 | Rubiadin |
Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections.
|
Inflammation or Immune System Disease
Breast Cancer
Colorectal Cancer
Liver Cancer
Cervical Cancer
Viral Infection
Bacterial Infection
Fungal Infection
Parasitic Infection
Epilepsy
Glucose Metabolism
Alzheimer's Disease
Liver Injury
|
/
|
| HY-N5025 | Bullatine A |
Bullatine A, a diterpenoid alkaloid, is a potent P2X7 antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Neurodegenerative Disease
Depression
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
/
|
| HY-P10709 | CREKA peptide |
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects.
|
|
/
|
| HY-P99940 | Remtolumab |
Remtolumab is a bispecific variable domain immunoglobulin molecule with human affinities for TNFα and IL-17 in the low pM range of Kd. Remtolumab can be used in research related to rheumatoid arthritis, psoriatic arthritis, and moderate-to-severe plaque psoriasis.
Species: Human |
|
/
|
| HY-P990130 | Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) |
Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) is a mouse-derived IgG2a κ type antibody, targeting to mouse/rat CD71/TfR1. Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) targets the transferrin receptor and binds to an extracellular domain for the transferrin receptor. Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) can be used for the research in drug delivery, especially for drug delivery to the brain.
Species: Mouse/Rat |
|
/
|
| HY-14655S | Sulfasalazine-d4 |
Sulfasalazine-d4 is the deuterium labeled Sulfasalazine. Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 ferroptosis inducer.
|
|
/
|
| HY-34748 | 3-Penten-2-one |
3-Penten-2-one (Ethylideneacetone) inhibits nitric oxide production and inducible nitric oxide synthase expression via heme oxygenase-1 induction in RAW264.7 macrophages activated with Lipopolysaccharides (HY-D1056) (LPS).
|
|
/
|
| HY-P991316 | KD014 |
KD014 (DX-2400) is a human monoclonal antibody that selectively targets MMP‑14. KD014 inhibits collagen degradation and regulates the polarization of macrophages toward an anti-inflammatory/anti-tumor phenotype. KD014 alleviates joint damage in rheumatoid arthritis and suppresses tumor growth and invasion. KD014 can be used in studies related to breast cancer and rheumatoid arthritis.
Species: Human |
|
/
|
| HY-159114 | Whole Glucan Particles |
Whole Glucan Particles is a Dectin-1a agonist. Whole Glucan Particles activates the innate immune system to improve the function of macrophages, monocytes and other immune cells.
|
|
/
|
| HY-P990651 | PY314 |
PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8+ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors.
Species: Human |
|
/
|
| HY-114354 | BODIPY FL alkyne |
BODIPY (BOD) FL alkyne is an alkyne-containing BODIPY fluorophore derivative. BODIPY FL alkyne is a bioorthogonal labeling reagent with low toxicity and extremely low non-specific reactivity, and it is widely used in fluorescent bioimaging. BODIPY FL alkyne specifically labels azide groups on intracellular glycoconjugates mainly via strain-promoted azide-alkyne cycloaddition (SPAAC), or mediates site-specific conjugation with proteins such as IL-33, and supports positive cross-linking with other probes (e.g., DBCO-SCy5) for dual labeling. With the advantages of high specificity and low background interference, BODIPY FL alkyne can be used in the research of related diseases such as asthma, atopic dermatitis and inflammatory bowel disease.
|
|
/
|
| HY-N15135 | Arabinoxylan (Medium viscosity) |
Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome.
|
|
/
|
| HY-125740 | Malvidin-3-glucoside chloride |
Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
/
|
| HY-P10216 | CAQK peptide |
CAQK peptide selectively binds to injured mouse brain. CAQK peptide selectively targets demyelinating areas and it is absent from healthy tissue. The CAQK peptide target is a proteoglycan complex upregulated in brain injuries and is used for drug delivery. CAQK peptide can penetrate the blood-brain barrier.
|
|
/
|
| HY-P990049 | Becotatug |
Becotatug (JMT-101) is a humanized IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR), and serves as the antibody component of the antibody-drug conjugate Becotatug vedotin (HY-171265). Becotatug specifically binds to the extracellular domain of EGFR, induces receptor internalization and degradation, blocks the EGFR signaling pathway, and mediates antibody-dependent cellular cytotoxicity. When conjugated to monomethyl auristatin E (MMAE) (HY-15162) via a valine-citrulline cleavable linker, Becotatug enables targeted delivery of cytotoxic drugs to EGFR-positive tumor cells. Becotatug can be used for research related to non-small cell lung cancer, nasopharyngeal carcinoma, and head and neck squamous cell carcinoma..
Species: Human |
|
/
|
| HY-Y0520S | Itaconic acid-13C5 |
|
/
|
|
| HY-113870 | 6-NBDG |
6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques.
|
|
/
|
| HY-D0835 | Hydroxylapatite (25-45 μm) |
Hydroxylapatite (Hydroxyapatite) (25-45 μm) is a natural form of calcium phosphate and is the main mineral component of bones and teeth. Hydroxylapatite (25-45 μm) can stimulate the expression and secretion of collagen in primary human dermal fibroblasts. Hydroxylapatite (25-45 μm) has good biocompatibility, bioactivity, and bone conductivity, making it suitable for targeted drug or nucleic acid delivery. Hydroxylapatite (25-45 μm) can be used in research on osteoarthritis, gout, and atherosclerosis.
Source: bones |
|
/
|
| HY-P10586A | Macrophage-activating lipopeptide 2 TFA |
Macrophage-activating lipopeptide 2 TFA is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 enhances endothelial nitric oxide synthase (eNOS) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 enhances endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL).
|
|
/
|
| HY-13740G | Resiquimod (GMP) |
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages.
|
|
/
|
| HY-P10646 | Muscle homing peptide M12 |
Muscle homing peptide M12 is a muscle-homing peptide with high affinity for skeletal muscle and cardiac muscle. Muscle homing peptide M12 can mediate the targeted delivery of loaded drugs to skeletal muscle and cardiac muscle tissues.
|
|
/
|
| HY-P99262 | Imalumab |
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer.
Species: Human |
|
/
|
| HY-P3507 | Dalazatide |
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.
|
|
/
|
| HY-P990094 | Trabikibart |
Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps.
Species: Human |
|
/
|
| HY-P3507A | Dalazatide TFA |
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.
|
|
/
|
| HY-12557 | γ-Glutamylvaline |
γ‑Glutamylvaline (γ-Glu-Val) is a calcium‑sensing receptor (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1 and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation.
|
|
/
|
| HY-P99505 | Ziltivekimab |
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease.
Species: Human |
|
/
|
| HY-Y0520R | Itaconic acid (Standard) |
Itaconic acid (Standard) is the analytical standard of Itaconic acid. This product is intended for research and analytical applications. Itaconic acid, a precursor of polymers, chemicals, and fuels, can be synthesized by many fungi. Itaconic acid also is a macrophage-specific metabolite. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. Itaconic acid has anti-inflammatory, anti-microbial and immunomodulatory effect.
|
|
/
|
| HY-P991049 | Atrosimab |
Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis.
Species: Human |
Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis
Fatty Liver Disease
|
/
|
| HY-128525 | Enterobactin |
Enterobactin is a siderophore produced by Gram-negative bacteria and has an extremely high affinity for iron. During the process of Salmonella typhimurium infecting macrophages, Enterobactin can not only help bacteria uptake iron but also reduce the antibacterial activity of macrophages. In addition, Enterobactin is also involved in the oxidative stress response of Escherichia coli. Enterobactin can be hydrolyzed by Fes in the cell and exert antioxidant effects by scavenging free radicals.
Source: Salmonella typhimurium |
|
/
|
| HY-W011927 | 4,4'-Sulfonyldiphenol |
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
|
Estrogen Receptor/ERR
Histone Methyltransferase
Thyroid Hormone Receptor
PI3K
Akt
mTOR
Androgen Receptor
Drug Derivative
Metabolic or Endocrine Disease
Breast Cancer
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
|
/
|
| HY-NP004 | Cobra Venom Factor |
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.).
|
|
/
|
| HY-P99486 | Briakinumab |
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
Species: Human |
|
/
|
| HY-P990798 | Anti-Mouse IFN gamma Antibody (XMG1.2) |
Anti-Mouse IFN gamma Antibody (XMG1.2) is a kind of rat-derived IgG1 antibody inhibitor, targeting to IFN-γ. Anti-Mouse IFN gamma Antibody (XMG1.2) can neutralize IFN-γ. Anti-Mouse IFN gamma Antibody (XMG1.2) can be used for the researches of cancer, inflammation and immunology, such as multiple myeloma and chronic inflammation.
Species: Mouse |
|
/
|
| HY-W020780 | mPEG5000-Mal |
mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses.
|
|
/
|
| HY-113491 | 3-Phosphoglyceric acid |
3-Phosphoglyceric acid is a metabolic intermediate in both glycolysis and the Calvin cycle. 3-Phosphoglyceric acid is involved in alveolar macrophage epigenetic regulation.
|
|
/
|
| HY-112624B | Dextran T70 (MW 70,000) |
Dextran 70,000 is a high molecular weight polysaccharide formed by glucose linked by α-(1→6) glycosidic bonds. Dextran 70,000 can expand blood volume through colloidal osmotic pressure effect and inhibit cell adhesion and platelet aggregation through steric hindrance. At the same time, Dextran 70,000 can be used as a drug carrier to achieve targeted delivery through endocytosis. Dextran 70,000 is biologically inert and has low immunogenicity. It can be used for clinical blood volume expansion, anti-thrombotic research, and evaluation of vascular permeability in in vitro experiments. It can also be combined with fluorescent dyes for cell tracking and drug delivery research. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance.
|
|
/
|
| HY-P72718 | CD5L Protein, Human (HEK293, His) |
CD5L protein regulates lipid metabolism and lipolysis by promoting fatty acid endocytosis into adipocytes via the CD36 receptor. This process, crucial for maintaining lipid homeostasis, leads to the degradation of triacylglycerols into glycerol and free fatty acids. CD5L Protein, Human (HEK293, His) is the recombinant human-derived CD5L protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P75792 | gp130/IL6ST Protein, Human (HEK293) |
Glycoprotein 130 (gp130) is a trans-membrane protein, is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) family. gp130 inhibits the cell growth and migration, decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67. gp130 shows anti-tumor, anti-inflammation and anti-nociceptive activity. gp130/IL6ST Protein, Human (HEK293) is a recombinant protein consisting of 596 amino acids (M23-I618) and is produced by HEK293 cells.
Species: Human; Source: HEK293 |
|
/
|
| HY-P703357 | NOD2 Protein, Human (sf9, Strep, Flag) |
NOD2 Protein, Human (sf9, Strep, Flag) is the recombinant human-derived NOD2, expressed by sf9 insect cells , with Strep, Flag labeled tag. ,
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P703644 | LRRK2 Protein, Human (Active, G2019S, sf9, GST) |
LRRK2 Protein, Human (sf9, GST, G2019S) is the recombinant human-derived LRRK2, expressed by sf9 insect cells , with GST labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P810149 | CD5L Antibody (YA9493) |
|
/
|
|
| HY-K0614 | Oil Red O Staining Kit for Cell Smears |
MCE Oil Red O Staining Kit for Cell Smears effectively stains lipid droplets of various sizes, including smaller lipid droplets, and preferentially adsorbs dye from the solvent. It is suitable for staining oil red O in cell smears, bone marrow smears, fluid smears, blood smears, and other samples. When using the kit, specimens should not be fixed with fixatives containing ethanol. If fixation is required, 10% formalin can be used. The positive staining result for fat typically appears orange-yellow to red, with the exact color varying depending on the lipid concentration. |
|
/
|
| HY-K3036 | IMDM (Iscove's Modified Dulbecco's Medium) |
MCE IMDM (Iscove's Modified Dulbecco's Medium) is an enriched formulation modified from DMEM, containing high concentrations of glucose, sodium pyruvate, amino acids, vitamins, HEPES buffer, selenium, and other essential nutrients. It is designed to meet the nutritional requirements for rapid cell proliferation and high-density culture, supporting a variety of cell types, including Jurkat cells, COS-7 cells, and macrophages. The product specifications are based on the 500 mL format, and larger volume packages are provided as multiples of this standard specification. |
|
/
|
Targets/Pathways






















































.jpg)


























































































































































